Stent with outer member to embolize an aneurysm

Information

  • Patent Grant
  • 9358140
  • Patent Number
    9,358,140
  • Date Filed
    Sunday, December 7, 2014
    9 years ago
  • Date Issued
    Tuesday, June 7, 2016
    7 years ago
Abstract
This invention is a stent to reduce blood flow to an aneurysm comprising: (a) an inner member, wherein this inner member is expanded from a first configuration to a second configuration within the parent vessel of an aneurysm, wherein the circumference of the second configuration is larger than the circumference of the first configuration; and (b) an outer member, wherein this outer member is less porous than the inner member, wherein this outer member covers or surrounds a first percentage of the surface area of the inner member when the inner structure is in the first configuration, wherein this outer member covers or surrounds a second percentage of the surface area of the inner member when the inner structure is in the second configuration, and wherein the second percentage less than the first percentage.
Description
FEDERALLY SPONSORED RESEARCH

Not Applicable


SEQUENCE LISTING OR PROGRAM

Not Applicable


BACKGROUND

1. Field of Invention


This invention relates to devices to treat aneurysms.


2. Background and Review of Related Art


An aneurysm is an abnormal bulging or ballooning of a blood vessel. Rupture of brain aneurysms can cause stroke, death, or disability. Around one-third of people who have a brain aneurysm that ruptures will die within 30 days of the rupture. Of the survivors, around half of them suffer some permanent loss of brain function. Many aneurysms are not identified until they rupture. However, identification of intact aneurysms is increasing due to increased outpatient imaging. Ruptured aneurysms must be treated to stop the bleeding or to prevent re-bleeding. Intact aneurysms may or may not be treated to prevent rupture, depending on their characteristics. Wide neck aneurysms are less prone to rupture, but are harder to treat. In the U.S., it has been estimated that over 10 million people have brain aneurysms and 30,000 people each year have a brain aneurysm that ruptures.


Several approaches can be used to treat brain aneurysms. These different approaches can be divided into three categories: (1) approaches involving treatment outside the vessel; (2) approaches involving treatment inside the aneurysm; and (3) approaches involving treatment in the parent vessel. Some of these approaches can be used together. Each of these approaches has some disadvantages, as discussed below.


1. Treatment Outside the Vessel


Clipping: Clipping is the application of a small clip to the aneurysm neck from outside the vessel to seal off the aneurysm. For most brain aneurysms, this involves invasive surgery including removing a section of the skull. Clipping began in the 1930's and is well-established. Clipping is more common in the U.S. than in Europe. Around half of all aneurysms are treated by clipping. There are many aneurysm clips in the prior art. However, due to its invasive nature, clipping is decreasing. Potential disadvantages of clipping can include: significant health risks associated with major surgery of this type; and long recovery times, even when the surgery itself goes well.


2. Treatment Inside the Aneurysm


Metal Coils: Metal coiling is the endovascular insertion of metal coils into the aneurysm to reduce blood flow and promote embolization in the aneurysm. Historically, metal coils have been platinum. Coils are more common in Europe than in the U.S. There are many examples of metal coils. Potential disadvantages of metal coils can include: low percentage of aneurysm volume filled (low occlusion is associated with a higher risk of rupture); compaction of coils over time; risk of recanalization; potential prolapse of coils into the parent vessel; difficulty later clipping aneurysms filled with metal coils, if needed; pressure from the coils on surrounding brain tissue; inability of coils to treat all aneurysms; and expense of metal coils (especially platinum coils).


Combination Metal/Textile/Foam/Gel Coils: Coils with a combination of metal and other materials can be used to try to achieve greater occlusion volume than metal coils alone. These other materials include textile, foam, and gel elements. Textile strands can be woven into the coils to add bulk. Coils can be covered with soft foam. Gel elements can be strung together into elongated structures. Examples of related art that appear to use this approach includes the following: U.S. Pat. No. 5,382,259 (Phelps et al.), U.S. Pat. No. 5,522,822 (Phelps et al.), U.S. Pat. No. 5,690,666 (Berenstein et al.), U.S. Pat. No. 5,718,711 (Berenstein et al.), U.S. Pat. No. 5,749,894 (Engelson), U.S. Pat. No. 5,976,162 (Doan et al.), U.S. Pat. No. 6,024,754 (Engelson), U.S. Pat. No. 6,299,619 (Greene, Jr. et al.), U.S. Pat. No. 6,602,261 (Greene, Jr. et al.), U.S. Pat. No. 6,723,108 (Jones et al.), U.S. Pat. No. 6,979,344 (Jones et al.), U.S. Pat. No. 7,070,609 (West), and U.S. Pat. No. 7,491,214 (Greene, Jr. et al.), and U.S. Patent Applications 20040158282 (Jones, Donald et al.), 20050267510 (Razack, Nasser), and 20060058834 (Do, Hiep et al.). Potential disadvantages of combination coils can include: remaining gaps between loops; compaction of coils over time; risk of recanalization; potential prolapse of coils into the parent vessel; difficulty clipping aneurysms filled with coils with metal components later if needed; pressure from the coils on surrounding brain tissue; inability of coils to treat all aneurysms; and expense of metal coils.


Inflatable Balloons: Approximately two decades ago, there were numerous efforts to treat aneurysms by permanently filling them with inflatable balloons. These efforts were largely abandoned due to the risks of balloon deflation, prolapse into the parent vessel, aneurysm rupture, and recanalization. There are, however, examples of relatively recent art that appear to use inflatable balloons to treat aneurysms: U.S. Pat. No. 6,569,190 (Whalen et al.) and U.S. Pat. No. 7,083,643 (Whalen et al.), and U.S. Patent Applications 20030135264 (Whalen et al.), 20030187473 (Berenstein, Alejandro et al.), 20060292206 (Kim, Steven et al.), 20070050008 (Kim, Steven et al.), and 20070055355 (Kim, Steven et al.). Potential disadvantages of using inflatable balloons to permanently fill aneurysms can include: balloon deflation; prolapse of the balloon into the parent vessel; aneurysm rupture due to balloon pressure; and recanalization.


Manually-Activated Mesh Occluders: Another approach to treating aneurysms involves inserting into the aneurysm a mesh structure, generally metal, that can be expanded or contracted by human-controlled mechanical motion so as to block the aneurysm neck and/or to fill the main volume of the aneurysm. For example, a wire structure can be inserted through the aneurysm neck in a narrow configuration and then transformed into an “hour-glass” shape that collapses to block the aneurysm neck when activated by a human controller. Examples of related art that appear to use this approach include the following: U.S. Pat. No. 5,928,260 (Chin et al.), U.S. Pat. No. 6,344,048 (Chin et al.), U.S. Pat. No. 6,375,668 (Gifford et al.), U.S. Pat. No. 6,454,780 (Wallace), U.S. Pat. No. 6,746,468 (Sepetka et al.), U.S. Pat. No. 6,780,196 (Chin et al.), and U.S. Pat. No. 7,229,461 (Chin et al.), and U.S. Patent Applications 20020042628 (Chin, Yem et al.), 20020169473 (Sepetka, Ivan et al.), 20030083676 (Wallace, Michael), 20030181927 (Wallace, Michael), 20040181253 (Sepetka, Ivan et al.), 20050021077 (Chin et al.), 20060155323 (Porter, Stephen et al.), 20070088387 (Eskridge, Joseph et al.), 20070106311 (Wallace, Michael et al.), and 20080147100 (Wallace, Michael). Potential disadvantages of such manually-activated metal occluders include: difficulty engaging the necks of wide-neck aneurysms; difficulty filling irregularly-shaped aneurysms with standard-shaped mesh structures; risk of rupture when pinching the aneurysm neck or pushing on the aneurysm walls; and protrusion of the proximal portion of “hour-glass” designs into the parent vessel.


Self-Expanding Standard-Shape Occluders: Another approach to treating aneurysms uses standard-shaped structures that self-expand when released into the aneurysm. For example, the structure may be a mesh of “shape memory” metal that automatically expands to a standard shape when released from the confines of the catheter walls. As another example, the structure may be a gel that expands to a standard shape when exposed to moisture. Examples of related art that appear to use this approach include the following: U.S. Pat. No. 5,766,219 (Horton), U.S. Pat. No. 5,916,235 (Guglielmi), 5,941,249 (Maynard), U.S. Pat. No. 6,409,749 (Maynard), U.S. Pat. No. 6,506,204 (Mazzocchi), U.S. Pat. No. 6,605,111 (Bose et al.), U.S. Pat. No. 6,613,074 (Mitelberg et al.), U.S. Pat. No. 6,802,851 (Jones et al.), U.S. Pat. No. 6,811,560 (Jones et al.), U.S. Pat. No. 6,855,153 (Saadat), U.S. Pat. No. 7,083,632 (Avellanet et al.), U.S. Pat. No. 7,306,622 (Jones et al.), and U.S. Pat. No. 7,491,214 (Greene, Jr. et al.), and U.S. Patent Applications 20030093097 (Avellanet, Ernesto et al.), 20030195553 (Wallace, Michael et al.), 20050033349 (Jones, Donald et al.), 20060052816 (Bates, Brian et al.), and 20060235464 (Avellanet, Ernesto et al.) and WIPO Patents WO/2006/084077 (Porter, Stephen et al.) and WO/1996/018343 (McGurk et. al.). Potential disadvantages of such self-expanding standard-shape structures can include: risk of prolapse into the parent vessel, especially for wide-neck aneurysms; difficulty occluding irregularly-shaped aneurysms with standard shape structures and associated risk of recanalization; and difficulty generating the proper amount of force (not too much or too little) when engaging the aneurysm walls with a standard-shaped self-expanding structure.


Self-Expanding Custom-Modeled Occluders: A variation on self-expanding standard-shape occluders (discussed above) are self-expanding occluders that are custom modeled before insertion so as to fit the shape of a particular aneurysm. As an example sequence—the aneurysm can be imaged, the image is used to custom model the occluding structure, the occluding structure is compressed into a catheter, the occluding structure is inserted into the aneurysm, and the occluding structure then self-expands to fill the aneurysm. The occluding structure may be made from a gel that expands upon contact with moisture. Examples of related art that appear to use this approach include the following: U.S. Pat. No. 5,766,219 (Horton), U.S. Pat. No. 6,165,193 (Greene, Jr. et al.), U.S. Pat. No. 6,500,190 (Greene, Jr. et al.), U.S. Pat. No. 7,029,487 (Greene, Jr. et al.), and U.S. Pat. No. 7,201,762 (Greene, Jr. et al.), and U.S. Patent Application 20060276831 (Porter, Stephen et al.). Potential disadvantages of self-expanding custom-modeled occluders can include: the complexity and expense of imaging and modeling irregularly-shaped aneurysms; difficulty compressing larger-size structures into a catheter; difficulty inserting the occluding structure in precisely the correct position; and difficulty getting a gelatinous surface to anchor solidly to aneurysm walls.


Congealing Liquid or Gel: Another approach to treating aneurysms involves filling an aneurysm with a liquid or gel that congeals rapidly. Examples of related art that appear to use this approach include the following: U.S. Pat. No. 6,569,190 (Whalen et al.), U.S. Pat. No. 6,626,928 (Raymond et al.), U.S. Pat. No. 6,958,061 (Truckai et al.), and U.S. Pat. No. 7,083,643 (Whalen et al.), and U.S. Patent Application 20030135264 (Whalen et al.). Potential disadvantages of a congealing liquid or gel can include: leakage of the congealing substance into the parent vessel, potentially causing a stroke; difficulty filling the entire aneurysm if the substance begins to congeal before the aneurysm is full; and seepage of toxic substances into the blood stream.


Biological or Pharmaceutical Agents: Biological and/or pharmaceutical agents can enhance the performance of a variety of mechanical treatment methods for aneurysms. For example, they can speed up the natural embolization process to occlude the aneurysm. Examples of related art that appear to use this approach include the following: U.S. Patent Applications 20060206139 (Tekulve, Kurt J.), 20070168011 (LaDuca, Robert et al.), and 20080033341 (Grad, Ygael). Currently, biological and/or pharmaceutical approaches are not sufficient as stand alone treatment approaches for many cases. Accordingly, they share most of the potential disadvantages of the baseline approach to which the biological or pharmaceutical agents are added.


Embolic-Emitting Expanding Members: Another approach involves an expanding member within the aneurysm that emits embolic elements into the aneurysm. Examples of such expanding members include bags, meshes, and nets. Examples of embolic elements include coils and congealing liquids. This can be viewed as another way to block the aneurysm neck while delivering embolics into the volume of the aneurysm. For example, the distal portion of an expanding bag may leak embolic elements into the aneurysm, but the proximal portion of the expanding member does not leak embolics into the parent vessel. Examples of related art that appear to use this approach include the following: U.S. Pat. No. 6,547,804 (Porter et al.) and U.S. Patent Applications 20040098027 (Teoh, Clifford et al.), 20060079923 (Chhabra, Manik et al.), and 20080033480 (Hardert, Michael). Potential disadvantages are as follows. Since the expanding member “leaks,” it may have insufficient expansion force to adequately anchor against the aneurysm walls or to seal off the aneurysm neck. As a result of poor anchoring, the bag may prolapse into the parent vessel. Also, as a result of poor sealing of the aneurysm neck, embolics may leak into the parent vessel.


Shape Memory Structures inside Expanding Members: A variation on the shape memory approach above involves the addition of an expanding member around the shape memory structure. Examples of related art that appear to use this approach include the following: U.S. Pat. No. 5,861,003 (Latson et al.), U.S. Pat. No. 6,346,117 (Greenhalgh), U.S. Pat. No. 6,350,270 (Roue), U.S. Pat. No. 6,391,037 (Greenhalgh), and U.S. Pat. No. 6,855,153 (Saadat). The potential disadvantages of this approach are similar to those for uncovered shape memory occluders: risk of prolapse into the parent vessel, especially for wide-neck aneurysms; difficulty occluding irregularly-shaped aneurysms with standard shape structures and associated risk of recanalization; and difficulty generating the proper amount of force (not too much or too little) when engaging the aneurysm walls with a standard-shaped self-expanding structure.


Accumulating Coils inside Expanding Members: A variation on the standard coiling approach above involves the addition of an expanding member around the accumulating coils. Examples of related art that appear to use this approach include the following: U.S. Pat. No. 5,334,210 (Gianturco), U.S. Pat. No. 6,585,748 (Jeffree), and U.S. Pat. No. 7,153,323 (Teoh et al.), and U.S. Patent Applications 20060116709 (Sepetka, Ivan et al.), 20060116712 (Sepetka, Ivan et al.), and 20060116713 (Sepetka, Ivan et al.). Potential disadvantages of this approach are similar to those for coils alone, including: compaction of coils over time; risk of recanalization due to “bumpy” coil-filled expanding member; difficulty clipping aneurysms filled with metal coils later if needed; pressure from the coils on surrounding brain tissue; inability to treat all aneurysms; and expense of metal coils (especially platinum coils).


3. Treatment in the Parent Vessel


Standard (High-Porosity) Stent: A stent is a structure that is inserted into a vessel in a collapsed form and then expanded into contact with the vessel walls. Standard stents are generally highly porous, metal, and cylindrical. A high-porosity stent allows blood to flow through the stent walls if there are any branching or secondary vessels in the vessel walls. Blood flow through a stent wall into a branching or secondary vessel is desirable, but blood flow through a stent wall into an aneurysm is not. Accordingly, a high-porosity stent in the parent vessel is not a good stand-alone aneurysm treatment. A high-porosity stent in the parent vessel can, however, help to keep coils or other embolic members from escaping out of the aneurysm into the parent vessel.


Examples of related art that appear to use this approach include the following: U.S. Pat. No. 6,096,034 (Kupiecki et al., 2000), U.S. Pat. No. 6,344,041 (Kupiecki et al., 2002), U.S. Pat. No. 6,168,592 (Kupiecki et al., 2001), and U.S. Pat. No. 7,211,109 (Thompson, 2007). Potential disadvantages of this approach can include many of the problems associated with use of the embolic members alone. For example, using a high-porosity stent in the parent vessel in combination with coils in the aneurysm still leaves the following disadvantages of using coils alone: low percentage of aneurysm volume filled (and low occlusion is associated with a higher risk of rupture); compaction of coils over time; significant risk of recanalization; difficulty clipping aneurysms filled with metal coils later if needed; pressure from the coils on surrounding brain tissue; inability of coils to treat all aneurysms; and expense of metal coils (especially platinum coils).


Uniformly Low-Porosity Stent: Another approach involves inserting a uniformly low-porosity stent into the parent vessel. The low-porosity stent blocks the flow of blood through the stent walls into the aneurysm, causing beneficial embolization of the aneurysm. For example, the stent may have one or more layers that are impermeable to the flow of liquid. Unlike a standard (high-porosity) stent, this approach can be used as a stand-alone aneurysm treatment. Examples of related art that appear to use this approach include the following: U.S. Pat. No. 5,645,559 (Hachtman et al., 1997), U.S. Pat. No. 5,723,004 (Dereume et al., 1998), U.S. Pat. No. 5,948,018 (Dereume et al., 1999), U.S. Pat. No. 6,165,212 (Dereume et al., 2000), U.S. Pat. No. 6,063,111 (Hieshima et al., 2000), U.S. Pat. No. 6,270,523 (Herweck et al., 2001), U.S. Pat. No. 6,331,191 (Chobotov, 2001), U.S. Pat. No. 6,342,068 (Thompson, 2002), U.S. Pat. No. 6,428,558 (Jones et al., 2002), U.S. Pat. No. 6,656,214 (Fogarty et al., 2003), U.S. Pat. No. 6,673,103 (Golds et al., 2004), U.S. Pat. No. 6,790,225 (Shannon et al., 2004), and U.S. Pat. No. 6,786,920 (Shannon et al., 2004), and U.S. Patent Application 20080319521 (Norris et al., 2008). Potential disadvantages of this approach can include: undesirably blocking blood flow to branching or secondary vessels that are close to the aneurysm and are covered by the stent wall; difficulty achieving a snug fit across the neck of the aneurysm if the parent vessel is curved, twisted, or forked; and poor attachment of the stent with the parent vessel wall due to the impermeable nature of the stent wall.


Uniformly Intermediate-Porosity Metal Stent: This approach pursues creation of a stent with a uniform intermediate porosity that provides a compromise between the benefits of a high-porosity stent in the parent vessel (good blood flow to nearby branching or secondary vessels) and the benefits of a low-porosity stents in the parent vessel (blocking blood flow to the aneurysm). Examples of related art that appear to use this approach include the following: U.S. Pat. No. 6,770,087 (Layne et al., 2004), U.S. Pat. No. 7,052,513 (Thompson, 2006), and U.S. Pat. No. 7,306,624 (Yodfat et al., 2007), and U.S. Patent Applications 20070207186 (Scanlon et al.,2007), 20070219619 (Dieck et al., 2007), 20070276470 (Tenne, 2007), 20070276469 (Tenne, 2007), and 20080039933 (Yodfat et al., 2008). The main potential disadvantage of this approach is that it may perform neither function very well. It may unreasonably block flow to a branching or secondary vessels (causing a stroke) and may inadequately block blood flow to the aneurysm (leaving it vulnerable to rupture).


Pre-Formed Differential Porosity Stent: This approach involves creating a stent with different levels of porosity for different wall areas, before the stent is inserted into the parent vessel. The goal is two-fold: (1) to place wall areas with high porosity over openings to branching or secondary vessels; and (2) to place wall areas with low porosity over the neck of the aneurysm. Examples of related art that appear to use this approach include the following: U.S. Pat. No. 5,769,884 (Solovay,1998), U.S. Pat. No. 5,951,599 (McCrory, 1999), U.S. Pat. No. 6,309,367 (Boock, 2001), U.S. Pat. No. 6,309,413 (Dereume et al., 2001), U.S. Pat. No. 6,165,212 (Dereume et al., 2000), U.S. Pat. No. 5,948,018 (Dereume et al.,1999), U.S. Pat. No. 5,723,004 (Dereume et al., 1998), and U.S. Pat. No. 7,186,263 (Golds et al., 2007), and U.S. Patent Applications 20070219610 (Israel, 2007), 20070239261 (Bose, et al., 2007), and 20080004653 (Sherman et al., 2008). Potential disadvantages of this approach include: difficultly matching a specific anatomic configuration (curvature, branching, neck size, etc) with a preformed stent; difficulty of precise placement of the stent to properly align the porous and non-porous areas with branching vessels and the aneurysm, respectively; and difficulty creating low porosity areas in a compressed state that maintain this low porosity in an expanded state.


Post-Implantation Filling Between Stent Wall and Vessel Wall: This approach fills the gap between the wall of the stent and the wall of the parent vessel with an embolizing substance such as a liquid or gel that solidifies after insertion. Examples of related art that appear to use this approach include the following: U.S. Pat. No. 5,769,882 (Fogarty et al., 1998) and U.S. Patent Application 20070150041 (Evans et al., 2007). Potential disadvantages of this approach include: difficulty injecting the embolizing substance through the stent wall without having it leak back into the parent vessel; leakage of embolizing liquid or gel between the stent and the parent vessel into the blood stream, where it blocks a downstream vessel and causes a stroke; challenges containing the embolic material within curving vessels or vessels with irregular walls; and difficulty using this method to fill narrow-neck aneurysms.


Post-Implantation Surface Modification: This approach creates different degrees of porosity in different wall areas after the stent is implanted. The goal is to decrease the porosity of the stent wall in the area of the aneurysm neck, but to leave the rest of the stent wall relatively porous to allow blood flow to branching or secondary members. Also, high porosity in other areas of the stent wall aids in the attachment and integration of the stent to the parent vessel. Unlike the preceding approach, this approach does not fill the gap between the stent wall and the parent vessel wall with some type of solidifying liquid, but rather modifies the wall of the stent itself This reduces the risk of embolic liquid or members leaking out between the stent and the parent vessel wall into the blood stream.


This approach remains relatively uncommon The few examples in the related art appear to expose one area of the stent wall to surface-modifying chemicals or energy emissions in order to decrease porosity of the stent wall in that area alone. Examples of related art that appear to use this approach include the following: U.S. Pat. No. 5,951,599 (McCrory, 1999) and U.S. Pat. No.7,156,871 (Jones et al., 2007). Potential disadvantages of this approach include: negative effects of surface-modifying chemicals seeping into the blood stream; negative effects of energy emissions on surrounding vessel or brain tissue; and difficulty adding enough matter to the stent wall covering the aneurysm neck by chemical or energy modification means, after stent implantation, to adequately reduce blood flow through the aneurysm neck.


To conclude this section, although there has been significant progress in developing options for treating brain aneurysms, there are still high rates of death and disability and still disadvantages to the treatment options available.


SUMMARY OF THIS INVENTION

This invention can be embodied in a stent system that is inserted into the parent vessel of an aneurysm in order to reduce blood flow to the aneurysm and promote embolization of the aneurysm. The stent wall includes an inner structure, such as an expandable metal mesh, that can be expanded from a compressed state to a resilient expanded state and an outer flexible layer, such as a flexible fabric net, that covers all or part of the inner structure. Embolic members are placed and retained in the gap between the inner structure and the outer layer in the area of the aneurysm neck in order to reduce blood flow to the aneurysm.


This invention can also be embodied in a stent to reduce blood flow to an aneurysm comprising: (a) an inner member, wherein this inner member is expanded from a first configuration to a second configuration within the parent vessel of an aneurysm, wherein the circumference of the second configuration is larger than the circumference of the first configuration; and (b) an outer member, wherein this outer member is less porous than the inner member, wherein this outer member covers or surrounds a first percentage of the surface area of the inner member when the inner structure is in the first configuration, wherein this outer member covers or surrounds a second percentage of the surface area of the inner member when the inner structure is in the second configuration, and wherein the second percentage less than the first percentage.





INTRODUCTION TO THE FIGURES


FIGS. 1 through 24 show possible embodiments of this stent, but do not limit the full generalizability of the claims.



FIG. 1 shows an opaque side view of one embodiment of this stent after it has been inserted and expanded within the parent blood vessel of an aneurysm.



FIG. 2 shows an alternative view of this same embodiment, with the two layers of the stent being transparent in order to allow a clearer view of the guidewires.



FIG. 3 shows an opaque side view of this same embodiment, except that a catheter to deliver embolic members has now been slid along the guidewires to reach an opening in the inner mesh structure.



FIG. 4 shows an alternative view of this same embodiment with the two layers of the stent being transparent in order to allow a clearer view of the catheter and the embolic members.



FIG. 5 shows an opaque side view of this same embodiment, except that a plurality of embolic members have now been inserted into the gap between the inner mesh structure and the outer flexible layer in the area of the aneurysm neck.



FIG. 6 shows an alternative view of this same embodiment with the two layers of the stent being transparent in order to allow a clearer view of the catheter and the embolic members.



FIGS. 7 and 8 show this same embodiment after the detachment and withdrawal of the guidewires and catheter.



FIG. 9 shows a close-up view of guidewires attached to the inside surface of a hexagonal opening in the inner mesh structure.



FIG. 10 shows a close-up view of the distal end of the catheter as it slides along the guidewires toward the inner mesh structure.



FIG. 11 shows a close-up view of the distal end of the catheter after it has completely slid along the guidewires to reach the inner mesh structure and be aligned with an opening in this inner mesh structure.



FIG. 12 shows a close-up view of embolic members being propelled through the catheter by a flow of sterile saline solution.



FIG. 13 shows a close-up view of a plurality of embolic members having been inserted into the gap between the inner mesh structure and the outer flexible layer, with both guidewires and catheter having been withdrawn.



FIGS. 14 and 15 show examples of this stent with a high-flexibility area of the outer flexible layer that is identified by radioopaque lines and that is positioned to cover the aneurysm neck.



FIGS. 16 through 18 show an example of a stent with a sliding outer flexible layer that is connected to an inner structure along arcuate ribs.



FIGS. 19 through 21 show an example of a stent with a sliding outer flexible layer that is held onto an inner structure by arcuate ribs.



FIGS. 22 through 24 show an example of a stent with a sliding outer flexible layer that is connected to an inner structure by partially-detachable connections.





DETAILED DESCRIPTION OF THE FIGURES


FIGS. 1 through 24 show possible embodiments of this stent. However, these embodiments are not exhaustive. These figures do not limit the full generalizability of the claims.



FIG. 1 shows an opaque side view of one embodiment of this stent, after it has been inserted and expanded within the parent blood vessel of an aneurysm. FIG. 1 also shows a cross-sectional side view of the parent blood vessel 103 with aneurysm 101 including aneurysm neck 102. In this embodiment, the stent system has a resilient inner structure 104, which is a metal mesh with a hexagonal pattern, and an outer flexible layer 105 that is configured like a net around the inner structure. FIG. 1 also shows two guidewires 106 that are attached to inner structure 104. The stent is shown in FIG. 1 in an already inserted and expanded configuration. Many methods of stent insertion and expansion, such as by catheter and balloon, are well known in the art and the precise methods of insertion and expansion are not central to this invention.


In this embodiment, the wall of the stent consists of two layers. The inner layer of the stent wall is an expandable and resilient metal mesh structure 104 with a hexagonal pattern. Many other types of expandable mesh structures may also be used. In various examples, this inner mesh structure may be made from stainless steel, a nickel-titanium alloy, cobalt chromium or a cobalt-chromium alloy, titanium or a titanium alloy, tantalum or a tantalum allow, or polymeric-based resin or another polymer. In this embodiment, the outer layer of the stent is a flexible fabric net 105. In various examples, the outer flexible layer may be made from latex, nylon, polyester, teflon, silicone, HDPE, polycarbonate urethane, polyether-polyamide copolymer, polyethylene terephthalate, polyolefin, polypropylene, polytetrafluorethylene, polytetrafluoroethene, polyurethane, or polyvinyl chloride.


In this embodiment, there is a gap between the inner mesh structure and the outer flexible layer and these layers are not connected to each other. In other examples of this invention, there may be no gap between these layers until embolic members are inserted between them in the area of the aneurysm neck. In other examples, the two layers may be connected at multiple points or seams in order to form separate pouches between the layers for more precise localized containment of the embolic members between the layers. In other examples, the wall may be comprised of more than two layers.



FIG. 2 shows an alternative view of the same embodiment of this stent that is shown in FIG. 1. FIG. 2 is the same as FIG. 1 except that FIG. 2 shows the two layers of the stent as transparent in order to allow a clearer view of two guidewires 106 that are attached to the inner mesh structure of the stent wall. In this embodiment, these two guidewires 106 were attached to the inner structure of the stent at a specific point before insertion of the stent and the operator has aligned this point with the aneurysm neck 102 during stent placement within the parent vessel 103. In this embodiment, these two guidewires 106 will be used to guide a catheter that delivers embolic members into the gap between the inner wall structure 104 and the outer flexible layer 105. In another example, guidewires need not be used; the catheter may be directed to the inner wall structure using real-time imaging and attached to the inner wall structure with a grasping or hooking mechanism.



FIG. 3 shows an opaque side view of the same embodiment of this stent that is shown in FIG. 1, except that a catheter 301 to deliver embolic members (including embolic member 302) has been slid along guidewires 106 to reach an opening in the inner mesh structure 104. In this embodiment, sterile embolic members (including 302) are propelled by a flow of sterile saline solution through catheter 301 for insertion into the gap between inner mesh structure 104 and outer flexible layer 105. The saline solution propels the embolic members through the catheter and into the gap, wherein the members expand and are trapped within the gap. The saline solution escapes through the openings in the mesh. In other examples, other means may be used to transport the embolic members along the catheter, such as miniature conveyor belts or rotating helix mechanisms.


In this embodiment, the embolic members are compressible micro-sponges that expand upon ejection from the catheter. In various examples, these micro-sponges may be made from cellulose, collagen, acetate, alginic acid, carboxy methyl cellulose, chitin, collagen glycosaminoglycan, divinylbenzene, ethylene glycol, ethylene glycol dimethylmathacrylate, ethylene vinyl acetate, hyaluronic acid, hydrocarbon polymer, hydroxyethylmethacrylate, methlymethacrylate, polyacrylic acid, polyamides, polyesters, polyolefins, polysaccharides, polyurethane, polyvinyl alcohol, silicone, urethane, and vinyl stearate. In other examples, the embolic members may be gels, beads, or coils.


In this embodiment, the embolic members (such as 302) are retained with the gap between the inner mesh structure 104 and outer flexible layer 105 because they expand upon ejection from the catheter 301 and can not exit the same opening in the inner mesh structure by which they entered this gap. In another example, the embolic members need not expand, but the opening by which they enter the gap may be closed when the catheter is removed to trap them within the gap.



FIG. 4 shows an alternative view of the same embodiment of this stent that is shown in FIG. 3, except that the two layers of the stent are transparent in order to allow a clearer view of catheter 301 and embolic members (including 302).



FIG. 5 shows an opaque side view of the same embodiment of this stent that is shown in FIG. 3, except that a plurality of embolic members (including 302) have now been delivered via catheter 301 and inserted into the gap between the inner mesh structure 104 and the outer flexible layer 105 in the area of the aneurysm neck. The flexibility of outer layer 105 allows it to distend into the aneurysm neck to more thoroughly block blood flow through the neck. A sufficient volume of embolic members has been inserted into this gap in the area of the aneurysm neck to occlude the flow of blood into aneurysm 101, thereby promoting embolization of the aneurysm.



FIG. 6 shows an alternative view of the same embodiment of this stent that is shown in FIG. 5, except that the two layers of the stent are transparent in order to allow a clearer view of catheter 301 and embolic members (including 302).



FIGS. 7 and 8 show the same embodiment, but after the detachment and withdrawal of the guidewires 106 and catheter 301. In this example, the guidewires may be detached from the inner mesh structure by application of a mild electric current and the catheter may be removed by simple mechanical withdrawal. Many other methods for detaching and removing guidewires and catheters are known in the prior art and the exact detachment and removal mechanisms are not central to this invention. Blood flow through the aneurysm neck is now largely blocked to promote embolization of the aneurysm, but other areas of the stent remain largely porous to foster integration with the walls of the parent vessel and to allow blood flow to any secondary vessels that may branch off from the parent vessel along the length of the stent.



FIGS. 9 through 13 show greater detail for one example of how the guidewires and catheter function to transport embolic members into the gap between the inner mesh structure and the outer flexible layer of the stent wall. In these figures: only small square patches of inner mesh structure 104 and outer flexible layer 105 are shown (indicated by dashed line borders); and the size of the gap between these two layers is exaggerated to provide a clearer view of how embolic members are inserted within this gap. In this example, guidewires 106 are attached to inner mesh structure 104 before the stent is inserted in the parent vessel and catheter 301 is guided to the inner mesh structure 104 by means of these guidewires.



FIG. 9 shows a close-up view of guidewires 106 attached to the inside surface of a hexagonal opening in inner mesh structure 104. FIG. 9 also shows outer flexible layer 105. FIG. 9 corresponds to a close-up view of a small area of FIGS. 1 and 2, the area in which guidewires 106 are attached to inner mesh structure 104. FIG. 10 shows a close-up view of the distal end 1001 of catheter 301 as it slides along guidewires 106 toward inner mesh structure 104. The other (proximal) end of catheter 301 remains outside the person's body. There are two holes, including 1002, that run longitudinally through opposite sides of the wall of catheter 301 and contain guidewires 106, enabling catheter 301 to slide along guidewires 106. FIG. 11 shows a close-up view of the distal end 1001 of catheter 301 after it has completely slid along guidewires 106 to reach inner mesh structure 104 and be aligned with one hexagonal opening of this structure.



FIG. 12 shows a close-up view of embolic members (including 302) being propelled through catheter 301 by a flow of sterile saline solution. In this example, the embolic members are micro-sponges that expand upon ejection from the catheter into the gap between the inner mesh structure 104 and outer flexible layer 105. FIG. 12 corresponds to a close-up view of a small area of FIGS. 3 and 4, the area in which the guidewires 106 are attached to the inner mesh structure 104.



FIG. 13 shows a close-up view of a plurality of embolic members having been inserted into the gap between the inner mesh structure 104 and outer flexible layer 105. Also, guidewires 106 and catheter 301 have been detached and withdrawn. FIG. 13 corresponds to a close-up view of a small area of FIGS. 7 and 8, the area in which the guidewires were attached to the inner mesh structure.



FIGS. 14 and 15 show an opaque side view of two examples of this stent that feature an outer flexible layer with differential flexibility. Having a stent with one area of the outer flexible layer that has greater flexibility and placing this area over the aneurysm neck has two advantages. First, it facilitates insertion of a substantial mass of embolic members into the gap between the inner mesh and the outer flexible layer in the area of the aneurysm neck in order to thoroughly occlude the aneurysm neck. Second, although the walls of the parent vessel resist migration of embolic members through the gap away from the aneurysm neck area, having less flexibility of the outer layer outside the aneurysm neck area provides additional resistance to possible migration of embolic members.


Specifically, FIGS. 14 and 15 show a stent, with an inner structural mesh 104 and an outer flexible net 105, having been inserted into parent vessel 103 of aneurysm 101 with aneurysm neck 102. FIGS. 14 and 15 also show a saddle-shaped area 1401 of the outer flexible net that has greater flexibility than the rest of the net. This saddle-shaped area with greater flexibility is positioned to cover the aneurysm neck when the stent is placed and expanded.


In FIGS. 14 and 15, the stent also features radioopaque lateral and longitudinal lines that help the operator to align the saddle-shaped area with the aneurysm neck during placement and expansion of the stent. In FIG. 14, the saddle-shaped area 1401 is identified for the operator by radioopaque longitudinal lines (including 1402) and lateral circumferential lines (including 1403) that intersect the outer boundaries of the saddle-shaped area. In this example, the operator positions the stent so that the aneurysm neck is centered, in each direction, between these radioopaque lines. In FIG. 15, the saddle-shaped area 1401 is identified by radioopaque longitudinal line 1501 and lateral circumferential line 1502 that intersect the center of the saddle-shaped area. In this example, the operator positions the stent so that the intersection of these lines is centered within the aneurysm neck.


In the examples shown in FIGS. 14 and 15: there is only one area of the outer flexible net with higher flexibility, this area is saddle-shaped, and this area spans approximately 15% of surface area of the stent. In other examples: there may be more than one area with higher flexibility to address multiple aneurysms, the area may have a different shape, and the area may span a higher or lower percentage of the surface area of the stent. In these examples, the radioopaque lines are lateral circumferential and longitudinal lines. In other examples, the radioopaque lines may trace the exact perimeter of the higher-flexibility area.


The following are particularly-relevant quotes from the specification thus far (including page and line numbers from the original Nov. 18, 2009 specification): “a stent system that is inserted into the parent vessel of an aneurysm in order to reduce blood flow to the aneurysm and promote embolization of the aneurysm” (Nov. 18, 2009 specification, page 10, lines 23-25); “stent wall includes an inner structure . . . that can be expanded from a compressed state to a resilient expanded state and an outer flexible layer . . . that covers . . . part of the inner structure” (Nov. 18, 2009 specification, page 10, lines 25-27); “one area of the outer flexible net . . . the area may span a higher or lower percentage of the surface area of the stent” (Nov. 18, 2009 specification, page 17, line 28-page 18, line 1); “features radioopaque lateral and longitudinal lines that help the operator to align the saddle-shaped area with the aneurysm neck during placement and expansion ” (Nov. 18, 2009 specification, page 17, lines 17-19); “layers may be connected at multiple points or seams” (Nov. 18, 2009 specification, page 13, lines 30-31); and “In this embodiment . . . these layers are not connected to each other” (Nov. 18, 2009 specification, page 13, lines 27-28).


In an example, an invention can be embodied in a device that is inserted into the parent vessel of an aneurysm in order to reduce blood flow to the aneurysm, comprising: an inner structure that can be expanded from a compressed state to a resilient expanded state within the parent vessel of the aneurysm; and an outer flexible layer that covers part of the inner structure, wherein this outer flexible layer spans a first percentage of the surface area of the inner structure before expansion of the inner structure, wherein this outer flexible layer spans a second percentage of the surface area of the inner structure after expansion of the inner structure, and wherein the first percentage is higher than the second percentage. In an example, the outer flexible layer can be less porous than the inner structure. In an example, this device can further comprise radioopaque markings that help the operator to align the outer flexible layer with the aneurysm neck.


In an example, this invention can be embodied in a device that is inserted into the parent vessel of an aneurysm in order to reduce blood flow to the aneurysm, comprising: an inner structure that can be expanded from a compressed state to a resilient expanded state within the parent vessel of the aneurysm; and an outer flexible layer that covers part of the inner structure, wherein the inner structure and outer flexible layer are connected to each other at multiple points or seams, and wherein one or more of these multiple points or seams are disconnected during expansion of the inner structure. In an example, the outer flexible layer can be less porous than the inner structure. In an example, this device can further comprise radioopaque markings that help the operator to align the outer flexible layer with the aneurysm neck.



FIGS. 16 through 24 show three examples of how this invention can be embodied in a device that is inserted into the parent vessel of an aneurysm in order to reduce blood flow to the aneurysm, comprising: an inner structure that can be expanded from a compressed state to a resilient expanded state within the parent vessel of the aneurysm; and an outer flexible layer that spans a first percentage of the circumference of the inner structure before expansion of the inner structure, wherein this outer flexible layer spans a second percentage of the circumference of the inner structure after expansion of the inner structure, and wherein the first percentage is higher than the second percentage.



FIGS. 16 through 18 show an example of a stent with a sliding outer flexible layer that is connected to an inner structure along arcuate ribs. FIG. 16 shows a longitudinal cross-sectional view of aneurysm 1601 and a longitudinal cross-sectional view of the parent vessel of the aneurysm. FIG. 16 also shows a longitudinal side view of a device that has been inserted into the parent vessel of aneurysm 1601. FIG. 16 shows this device after the device has been placed within the parent vessel and after an outer flexible layer (1604) has been aligned with the neck of the aneurysm, but before an inner structure (1602) has been expanded. In this example, this device comprises: inner structure (1602) that can be expanded from a compressed state to a resilient expanded state; outer flexible layer (1604) that spans part of inner structure 1602; multiple points or seams (including 1605 and 1606) by which outer flexible layer 1604 is connected to inner structure 1602; multiple arcuate ribs or tracks 1607 to which the multiple points or seams (including 1605 and 1606) are attached; and inflatable member 1603 which is used to expand inner structure 1602.


In this example, inner structure 1602 is an expandable resilient tubular mesh. In this example, outer flexible layer 1604 is a saddle-shaped net, patch, covering, and/or liner with a lower porosity than inner structure 1602. In an example, outer flexible layer 1604 can have smaller surface pores or openings (as shown in FIGS. 9 through 13) and/or be less permeable to blood than inner structure 1602. In an example, outer flexible layer 1604 can be impermeable to blood. In various examples, outer flexible layer 1604 can have shapes other than a saddle shape. In an example, outer flexible layer 1604 can have a semi-tubular shape. In this example, outer flexible layer 1604 spans a first percentage of the circumference of inner structure 1602 before expansion of inner structure 1602. In this example, outer flexible layer 1604 spans (a maximum of) approximately 75% of the circumference of inner structure 1602 before expansion of inner structure 1602. In other examples, an outer flexible layer can span a pre-expansion percentage of the circumference of the inner structure in the range of 50% to 100%.


In an example, arcuate ribs or tracks (such as 1607) can encircle the entire circumference of inner structure 1602. In an example, arcuate ribs or tracks (such as 1607) can partially encircle a portion of the circumference of inner structure 1602. In an example, arcuate ribs or tracks can fully or partially encircle the circumference of inner structure 1602 in a plane which is substantially perpendicular to the longitudinal axis of inner structure 1602. In an example, arcuate ribs or tracks (such as 1607) can expand or telescope longer when inner structure 1602 expands.


In an example, inflatable member 1603 can be a balloon. In an example, inflatable member 1603 can be inflated by filling it with a liquid, such as saline or contrast media. In an example, inflatable member 1603 can be inflated by filling it with a gas, such as carbon dioxide. In an example, this device can further comprise imaging-detectable markings (as shown in FIGS. 14 and 15) to help an operator align outer flexible layer 1604 with the neck of the aneurysm. In an example, this device can further comprise radioopaque markings to help an operator align outer flexible layer 1604 with the neck of the aneurysm. In an example, this device can further comprise ultrasound-detectable markings to help an operator align outer flexible layer 1604 with the neck of the aneurysm. In an example, three-dimensional ultrasound imaging can be used to guide placement of the device and/or to align the outer layer 1604 with the neck of the aneurysm.



FIG. 16 shows this device before inner structure 1602 is expanded by expansion of inflatable member 1603. FIG. 17 shows this same device after inner structure 1602 has been expanded by expansion of inflatable member 1603. As shown in FIG. 17, the (maximum) percentage of the surface area of inner structure 1602 which is spanned by outer flexible layer 1604 is smaller after expansion of inner structure 1602. This is because outer flexible layer 1604 has been expanded less, or not at all, during the expansion of inner structure 1602. As also shown in FIG. 17, the (maximum) percentage of the circumference of inner structure 1602 which is spanned by outer flexible layer 1604 is smaller after the expansion of inner structure 1602. This is because outer flexible layer 1604 has been expanded less, or not at all, during the expansion of inner structure 1602. In this example, the post-expansion percentage of the circumference of inner structure 1602 which is spanned by outer flexible layer 1604 is approximately 30%. In an example, this percentage can be in the range of 20% to 60%


As shown in FIGS. 16 and 17, outer flexible layer 1604 spans a first (pre-expansion) percentage of the circumference of inner structure 1602 before inner structure 1602 is expanded, spans a second (post-expansion) percentage of the circumference of inner structure 1602 after inner structure is expanded, and the first percentage is larger than the second percentage. This is because the surface area of the outer flexible layer 1604 expands less (or not at all) relative to the expansion of inner structure 1602. This differential expansion of outer flexible layer 1604 vs. inner structure 1602 creates a region of low-porosity over the aneurysm neck. This advantageously helps to block blood flow through the aneurysm without deleteriously blocking blood flow to nearby branching blood vessels (such as the small branching vessel shown on side of the parent vessel which is opposite the aneurysm neck).


In the example shown in FIGS. 16 and 17, outer flexible layer 1604 has less expansion (or none at all) compared to the expansion of inner structure 1602 because outer flexible layer 1604 is connected to inner structure 1602 by means of multiple points or seams (such as 1605 and 1606) which are able to slide along multiple arcuate ribs or tracks (such as 1607) along the circumference of inner structure 1602. In this example, when inner structure 1602 is expanded, outer flexible layer 1604 does not expand. In this example, when inner structure 1602 is expanded, outer flexible layer 1604 slides on the arcuate ribs or tracks via multiple points or seams (including 1606). This is why, in this example, outer flexible layer 1604 (which does not expand) covers a smaller percentage of the surface area of inner structure 1602 (which does expand) after inner structure 1602 has been expanded.


In an example, inner structure 1602 and outer flexible layer 1604 can be connected at multiple points or seams and one or more of these points or seams can move along the circumference of the inner structure during expansion of the inner structure. In an example, inner structure 1602 and outer flexible layer 1604 can be connected at multiple points or seams and one or more of these points or seams can move on a track along the circumference of the inner structure during expansion of the inner structure.


In the example shown in FIGS. 16 and 17, a first subset (including 1606) of the multiple points or seams can slide along arcuate ribs or tracks (such as 1607) when inner structure 1602 expands, but a second subset (including 1605) of the multiple points or seams does not slide. Having a first subset (including 1606) of multiple points or seams slide allows outer flexible layer 1604 to not expand when inner structure 1602 expands. Having a second subset (including 1605) of multiple points or seams which do not slide helps to keep outer flexible layer 1604 properly positioned over the aneurysm neck during expansion of inner structure 1602. FIG. 18 shows the same device that was shown in FIGS. 16 and 17, but in a final configuration after inflatable member 1603 has been removed.



FIGS. 19 through 21 show an example of a stent with a sliding outer flexible layer that is held onto an inner structure by arcuate ribs. FIG. 19 shows this device before inner structure (1602) has been expanded. The device shown in FIG. 19 comprises: inner structure (1602) that can be expanded from a compressed state to a resilient expanded state; outer flexible layer (1604) that spans part of inner structure 1602; multiple arcuate ribs (including 1901) outside outer flexible layer 1604; and inflatable member 1603 which is used to expand inner structure 1602. Similar to the previous example, inner structure 1602 is an expandable resilient tubular mesh. Also, outer flexible layer 1604 is again a saddle-shaped net, patch, covering, and/or liner with a lower porosity than inner structure 1602. FIG. 19 shows this device before inner structure 1602 is expanded. FIG. 20 shows this device after inner structure 1602 has been expanded. FIG. 21 shows this device in a final configuration after inflatable member 1603 has been removed.


However, in this example, arcuate ribs (such as 1901) are outside outer flexible layer 1604. In this example, arcuate ribs (such as 1901) loosely hold outer flexible layer 1604 against inner structure 1602, but still allow outer flexible layer 1604 to slide around the circumference of inner structure 1602 when inner structure 1602 expands. In an example, these arcuate ribs can encircle the entire circumference of inner structure 1602. In an example, these arcuate ribs can partially encircle a portion of the circumference of inner structure 1602. In an example, these arcuate ribs can expand or telescope longer when inner structure 1602 expands. In an example, outer flexible layer 1604 is between inner structure 1602 and a plurality of expandable arcuate ribs, wherein these ribs span all or part of the circumference of inner structure, and wherein the outer flexible layer can slide between the inner structure and the expandable arcuate ribs during expansion of the inner structure. In an alternative example, the use of a flexible third layer (such as a tubular net or mesh) can serve the same function as arcuate ribs, instead of using arcuate ribs. In an example, the wall of the device may be comprised of more than two layers.



FIGS. 22 through 24 show an example of a stent with a sliding outer flexible layer that is connected to an inner structure by partially-detachable connections. FIG. 22 shows this device before an inner structure (1602) has been expanded. The device shown in FIG. 22 comprises: inner structure (1602) that can be expanded from a compressed state to a resilient expanded state; outer flexible layer (1604) that spans part of inner structure 1602; multiple points or seams (including 2201 and 2202) by which outer flexible layer 1604 is connected to inner structure 1602; and inflatable member 1603 which is used to expand inner structure 1602. Similar to the previous example, inner structure 1602 is again an expandable resilient tubular mesh and outer flexible layer 1604 is again a saddle-shaped net, patch, covering, and/or liner with a lower porosity than inner structure 1602. FIG. 22 shows this device before inner structure 1602 is expanded. FIG. 23 shows this device after inner structure 1602 has been expanded. FIG. 24 shows this device in a final configuration after inflatable member 1603 has been removed.


In this example, a subset (including 2202) of multiple points or seams (including 2201 and 2202) become disconnected when inner structure 1602 expands. This is another way to allow inner structure 1602 to expand without making outer flexible layer 1604 also expand. The subset of points or seams (including 2201) which remain connected when inner structure 1602 expands help to keep outer flexible layer 1604 positioned over the aneurysm neck. This is another way to create a low-porosity region over the aneurysm neck to block blood flow to the aneurysm without blocking blood flow to nearby branching vessels. In an example, the subset of multiple points or seams (including 2202) can become disconnected due to the shearing force of expansion. In an example, the subset of multiple points or seams (including 2202) can become disconnected via melting due to the application of an electrical charge. In an example, inner structure 1602 and outer flexible layer 1604 can be connected at multiple points or seams, wherein these one or more of these points or seams are disconnected during expansion of the inner structure.


In an example, this invention can be embodied in a stent to reduce blood flow to an aneurysm comprising: (a) an inner member, wherein this inner member is expanded from a first configuration to a second configuration within the parent vessel of an aneurysm, wherein the circumference of the second configuration is larger than the circumference of the first configuration; and (b) an outer member, wherein this outer member is less porous than the inner member, wherein this outer member covers or surrounds a first percentage of the surface area of the inner member when the inner structure is in the first configuration, wherein this outer member covers or surrounds a second percentage of the surface area of the inner member when the inner structure is in the second configuration, and wherein the second percentage is lower than the first percentage. In an example, the second percentage can be at least 10% less than the first percentage.

Claims
  • 1. A stent to reduce blood flow to an aneurysm comprising: (a) an inner member, wherein this inner member is expanded from a first configuration to a second configuration within a parent vessel of an aneurysm, wherein a circumference of the second configuration is larger than a circumference of the first configuration; and(b) an outer member, wherein said outer member is less porous than the inner member, wherein said outer member covers or surrounds a first percentage of a surface area of the inner member when the inner member is in the first configuration, wherein said outer member covers or surrounds a second percentage of the surface area of the inner member when the inner member is in the second configuration, wherein the second percentage is lower than the first percentage, wherein the outer member is between the inner member and a plurality of expandable arcuate ribs, wherein said plurality of expandable arcuate ribs span all or part of the circumference of inner member, and wherein the outer member can slide between the inner member and said plurality of arcuate ribs during expansion of the inner member.
CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation-in-part of U.S. patent application Ser. No. 12/592,116—entitled “Stent with a Net Layer to Embolize an Aneurysm” filed on Nov. 18, 2009 by Robert Connor and Muhammad Tariq Janjua—the entirety of which is incorporated by reference.

US Referenced Citations (1119)
Number Name Date Kind
4364392 Strother et al. Dec 1982 A
4994069 Ritchart et al. Feb 1991 A
5226889 Sheiban Jul 1993 A
5304132 Jang Apr 1994 A
5334210 Gianturco Aug 1994 A
5350397 Palermo et al. Sep 1994 A
5370691 Samson Dec 1994 A
5382259 Phelps et al. Jan 1995 A
5405379 Lane Apr 1995 A
5411549 Peters May 1995 A
5423829 Pham et al. Jun 1995 A
5443478 Purdy Aug 1995 A
5522822 Phelps et al. Jun 1996 A
5536252 Imran et al. Jul 1996 A
5582619 Ken Dec 1996 A
5603722 Phan et al. Feb 1997 A
5624449 Pham et al. Apr 1997 A
5624461 Mariant Apr 1997 A
5624685 Takahashi et al. Apr 1997 A
5639277 Mariant et al. Jun 1997 A
5645559 Hachtman et al. Jul 1997 A
5649949 Wallace et al. Jul 1997 A
5690666 Berenstein et al. Nov 1997 A
5690667 Gia Nov 1997 A
5693088 Lazarus Dec 1997 A
5702361 Evans et al. Dec 1997 A
5718711 Berenstein et al. Feb 1998 A
5723004 Dereume et al. Mar 1998 A
5733294 Forber et al. Mar 1998 A
5733329 Wallace et al. Mar 1998 A
5743905 Eder et al. Apr 1998 A
5749891 Ken et al. May 1998 A
5749894 Engelson May 1998 A
5766160 Samson et al. Jun 1998 A
5766219 Horton Jun 1998 A
5769882 Fogarty et al. Jun 1998 A
5769884 Solovay Jun 1998 A
5776097 Massoud Jul 1998 A
5785679 Abolfathi et al. Jul 1998 A
5795331 Cragg et al. Aug 1998 A
5800453 Gia Sep 1998 A
5800455 Palermo et al. Sep 1998 A
5826587 Berenstein et al. Oct 1998 A
5833657 Reinhardt et al. Nov 1998 A
5833705 Ken et al. Nov 1998 A
5836966 St. Germain Nov 1998 A
5853418 Ken et al. Dec 1998 A
5868780 Lashinski et al. Feb 1999 A
5873907 Frantzen Feb 1999 A
5888546 Ji et al. Mar 1999 A
5891130 Palermo et al. Apr 1999 A
5894022 Ji et al. Apr 1999 A
5911731 Pham et al. Jun 1999 A
5916235 Guglielmi Jun 1999 A
5922019 Hankh et al. Jul 1999 A
5925059 Palermo et al. Jul 1999 A
5928260 Chin et al. Jul 1999 A
5935145 Villar et al. Aug 1999 A
5935148 Villar et al. Aug 1999 A
5938697 Killion et al. Aug 1999 A
5941249 Maynard Aug 1999 A
5941888 Wallace et al. Aug 1999 A
5948018 Dereume et al. Sep 1999 A
5951599 McCrory Sep 1999 A
5957948 Mariant Sep 1999 A
5957975 Lafont et al. Sep 1999 A
5964797 Ho Oct 1999 A
5980514 Kupiecki et al. Nov 1999 A
6004338 Ken et al. Dec 1999 A
6007573 Wallace et al. Dec 1999 A
6013084 Ken et al. Jan 2000 A
6015424 Rosenbluth et al. Jan 2000 A
6015433 Roth Jan 2000 A
6017977 Evans et al. Jan 2000 A
6024754 Engelson Feb 2000 A
6024765 Wallace et al. Feb 2000 A
6027526 Limon et al. Feb 2000 A
6033423 Ken et al. Mar 2000 A
6036720 Abrams et al. Mar 2000 A
6063070 Eder May 2000 A
6063104 Villar et al. May 2000 A
6063111 Hieshima et al. May 2000 A
6071298 Lashinski et al. Jun 2000 A
6074407 Levine et al. Jun 2000 A
6086610 Duerig et al. Jul 2000 A
6093199 Brown et al. Jul 2000 A
6096021 Helm et al. Aug 2000 A
6096034 Kupiecki et al. Aug 2000 A
6096175 Roth Aug 2000 A
6099546 Gia Aug 2000 A
6099559 Nolting Aug 2000 A
6123712 Di Caprio et al. Sep 2000 A
6123714 Gia et al. Sep 2000 A
6136011 Stambaugh Oct 2000 A
6139564 Teoh Oct 2000 A
6140452 Felt et al. Oct 2000 A
6143007 Mariant et al. Nov 2000 A
6149681 Houser et al. Nov 2000 A
6159165 Ferrera et al. Dec 2000 A
6159238 Killion et al. Dec 2000 A
6165193 Greene et al. Dec 2000 A
6165212 Dereume et al. Dec 2000 A
6168592 Kupiecki et al. Jan 2001 B1
6168615 Ken et al. Jan 2001 B1
6168622 Mazzocchi Jan 2001 B1
6187027 Mariant et al. Feb 2001 B1
6190406 Duerig et al. Feb 2001 B1
6193728 Ken et al. Feb 2001 B1
6210429 Vardi et al. Apr 2001 B1
6221066 Ferrera et al. Apr 2001 B1
6231586 Mariant May 2001 B1
6231597 Deem et al. May 2001 B1
6238403 Greene et al. May 2001 B1
6254592 Samson et al. Jul 2001 B1
6258115 Dubrul Jul 2001 B1
6258117 Camrud et al. Jul 2001 B1
6270523 Herweck et al. Aug 2001 B1
6273910 Limon Aug 2001 B1
6273911 Cox et al. Aug 2001 B1
6280457 Wallace et al. Aug 2001 B1
6281263 Evans et al. Aug 2001 B1
6287318 Villar et al. Sep 2001 B1
6299619 Greene et al. Oct 2001 B1
6306177 Felt et al. Oct 2001 B1
6309367 Boock Oct 2001 B1
6309413 Dereume et al. Oct 2001 B1
6312421 Boock Nov 2001 B1
6312463 Rourke et al. Nov 2001 B1
6331191 Chobotov Dec 2001 B1
6335384 Evans et al. Jan 2002 B1
6342068 Thompson Jan 2002 B1
6344041 Kupiecki et al. Feb 2002 B1
6344048 Chin et al. Feb 2002 B1
6346117 Greenhalgh Feb 2002 B1
6350270 Roue Feb 2002 B1
6371972 Wallace et al. Apr 2002 B1
6375668 Gifford et al. Apr 2002 B1
6375669 Rosenbluth et al. Apr 2002 B1
6379373 Sawhney et al. Apr 2002 B1
6383174 Eder May 2002 B1
6391037 Greenhalgh May 2002 B1
6395018 Castaneda May 2002 B1
6398803 Layne et al. Jun 2002 B1
6406490 Roth Jun 2002 B1
6409721 Wheelock et al. Jun 2002 B1
6409749 Maynard Jun 2002 B1
6416543 Hilaire et al. Jul 2002 B1
6419685 Di Caprio et al. Jul 2002 B2
6423085 Murayama et al. Jul 2002 B1
6428558 Jones et al. Aug 2002 B1
6432128 Wallace et al. Aug 2002 B1
6454738 Tran et al. Sep 2002 B1
6454780 Wallace Sep 2002 B1
6458119 Berenstein et al. Oct 2002 B1
6463317 Kucharczyk et al. Oct 2002 B1
6468302 Cox et al. Oct 2002 B2
6471672 Brown et al. Oct 2002 B1
6475233 Trozera Nov 2002 B2
6475236 Roubin et al. Nov 2002 B1
6485509 Killion et al. Nov 2002 B2
6485510 Camrud et al. Nov 2002 B1
6497722 Von Oepen et al. Dec 2002 B1
6500190 Greene et al. Dec 2002 B2
6506201 Di Caprio et al. Jan 2003 B2
6506204 Mazzocchi Jan 2003 B2
6511468 Cragg et al. Jan 2003 B1
6511505 Cox et al. Jan 2003 B2
6520985 Burpee et al. Feb 2003 B1
6520987 Plante Feb 2003 B1
6527919 Roth Mar 2003 B1
6533801 Wallace et al. Mar 2003 B2
6547804 Porter et al. Apr 2003 B2
6551305 Ferrera et al. Apr 2003 B2
6558414 Layne May 2003 B2
6569190 Whalen et al. May 2003 B2
6569193 Cox et al. May 2003 B1
6579305 Lashinski Jun 2003 B1
6579314 Lombardi et al. Jun 2003 B1
6585748 Jeffree Jul 2003 B1
6585753 Eder et al. Jul 2003 B2
6585758 Chouinard et al. Jul 2003 B1
6589230 Gia et al. Jul 2003 B2
6599316 Vardi et al. Jul 2003 B2
6602261 Greene et al. Aug 2003 B2
6602269 Wallace et al. Aug 2003 B2
6602284 Cox et al. Aug 2003 B2
6603994 Wallace et al. Aug 2003 B2
6605056 Eidenschink et al. Aug 2003 B2
6605101 Schaefer et al. Aug 2003 B1
6605111 Bose et al. Aug 2003 B2
6613074 Mitelberg et al. Sep 2003 B1
6616617 Ferrera et al. Sep 2003 B1
6623493 Wallace et al. Sep 2003 B2
6629947 Sahatjian et al. Oct 2003 B1
6645237 Klumb et al. Nov 2003 B2
6652576 Stalker Nov 2003 B1
6656214 Fogarty et al. Dec 2003 B1
6660020 Wallace et al. Dec 2003 B2
6660032 Klumb et al. Dec 2003 B2
6669719 Wallace et al. Dec 2003 B2
6669723 Killion et al. Dec 2003 B2
6673103 Golds et al. Jan 2004 B1
6676701 Rourke et al. Jan 2004 B2
6689148 Sawhney et al. Feb 2004 B2
6699277 Freidberg et al. Mar 2004 B1
6719783 Lentz et al. Apr 2004 B2
6723108 Jones et al. Apr 2004 B1
6746468 Sepetka et al. Jun 2004 B1
6746475 Rivelli Jun 2004 B1
6770087 Layne et al. Aug 2004 B2
6780196 Chin et al. Aug 2004 B2
6786920 Shannon et al. Sep 2004 B2
6790225 Shannon et al. Sep 2004 B1
6796997 Penn et al. Sep 2004 B1
6802851 Jones et al. Oct 2004 B2
6811560 Jones et al. Nov 2004 B2
6814754 Greenhalgh Nov 2004 B2
6818018 Sawhney Nov 2004 B1
6833003 Jones et al. Dec 2004 B2
6835203 Vardi et al. Dec 2004 B1
6855153 Saadat Feb 2005 B2
6855154 Abdel-Gawwad Feb 2005 B2
6860899 Rivelli Mar 2005 B1
6899730 Rivelli May 2005 B1
6913618 Denardo et al. Jul 2005 B2
6916337 Roth Jul 2005 B2
6929658 Freidberg et al. Aug 2005 B1
6958061 Truckai et al. Oct 2005 B2
6962602 Vardi et al. Nov 2005 B2
6964657 Cragg et al. Nov 2005 B2
6969401 Marotta et al. Nov 2005 B1
6979344 Jones et al. Dec 2005 B2
6984240 Ken et al. Jan 2006 B1
6994721 Israel Feb 2006 B2
7001422 Escamilla et al. Feb 2006 B2
7014645 Greene et al. Mar 2006 B2
7029486 Schaefer et al. Apr 2006 B2
7029487 Greene et al. Apr 2006 B2
7033374 Schaefer et al. Apr 2006 B2
7033385 Eder et al. Apr 2006 B2
7037327 Salmon et al. May 2006 B2
7037330 Rivelli et al. May 2006 B1
7041129 Rourke et al. May 2006 B2
7052510 Richter May 2006 B1
7052513 Thompson May 2006 B2
7060091 Killion et al. Jun 2006 B2
7070609 West Jul 2006 B2
7081129 Chobotov Jul 2006 B2
7083632 Avellanet et al. Aug 2006 B2
7083640 Lombardi et al. Aug 2006 B2
7083643 Whalen et al. Aug 2006 B2
7112216 Gregorich Sep 2006 B2
7118656 Roth Oct 2006 B2
7128736 Abrams et al. Oct 2006 B1
7137993 Acosta et al. Nov 2006 B2
7141063 White et al. Nov 2006 B2
7147655 Chermoni Dec 2006 B2
7147659 Jones Dec 2006 B2
7147660 Chobotov et al. Dec 2006 B2
7147661 Chobotov et al. Dec 2006 B2
7153323 Teoh et al. Dec 2006 B1
7156871 Jones et al. Jan 2007 B2
7182744 Yamasaki et al. Feb 2007 B2
7186263 Golds et al. Mar 2007 B2
7195636 Avellanet et al. Mar 2007 B2
7195648 Jones et al. Mar 2007 B2
7201762 Greene et al. Apr 2007 B2
7211109 Thompson May 2007 B2
7220270 Sawhney et al. May 2007 B2
7226475 Lenz et al. Jun 2007 B2
7229461 Chin et al. Jun 2007 B2
7231260 Wallace et al. Jun 2007 B2
7232461 Ramer Jun 2007 B2
7235098 Palmaz Jun 2007 B2
7238194 Monstadt et al. Jul 2007 B2
7241301 Thramann et al. Jul 2007 B2
7241308 Andreas et al. Jul 2007 B2
7244261 Lorenzo et al. Jul 2007 B2
7247159 Lorenzo et al. Jul 2007 B2
7288112 Denardo et al. Oct 2007 B2
7294123 Jones et al. Nov 2007 B2
7294137 Rivelli et al. Nov 2007 B2
7294146 Chew et al. Nov 2007 B2
7300459 Heuser Nov 2007 B2
7300661 Henson et al. Nov 2007 B2
7306598 Truckai et al. Dec 2007 B2
7306622 Jones et al. Dec 2007 B2
7306624 Yodfat et al. Dec 2007 B2
7309351 Escamilla et al. Dec 2007 B2
7309352 Eder et al. Dec 2007 B2
7311861 Lanphere et al. Dec 2007 B2
7323005 Wallace et al. Jan 2008 B2
7326225 Ferrera et al. Feb 2008 B2
7326236 Andreas et al. Feb 2008 B2
7331974 Schaefer et al. Feb 2008 B2
7338511 Mirigian et al. Mar 2008 B2
7361367 Henson et al. Apr 2008 B2
7374568 Whalen et al. May 2008 B2
7384426 Wallace et al. Jun 2008 B2
7402169 Killion et al. Jul 2008 B2
7410482 Murphy et al. Aug 2008 B2
7413573 Hartley et al. Aug 2008 B2
7414038 Kinugasa et al. Aug 2008 B2
7442382 Henson et al. Oct 2008 B2
7449236 Lanphere et al. Nov 2008 B2
7455753 Roth Nov 2008 B2
7481821 Fogarty et al. Jan 2009 B2
7483558 Greene et al. Jan 2009 B2
7485123 Porter Feb 2009 B2
7491214 Greene et al. Feb 2009 B2
7491226 Palmaz et al. Feb 2009 B2
7491229 Eder et al. Feb 2009 B2
7520893 Rivelli Apr 2009 B2
7537609 Davidson et al. May 2009 B2
7547321 Silvestri et al. Jun 2009 B2
7563270 Gumm Jul 2009 B2
7569066 Gerberding et al. Aug 2009 B2
7572288 Cox Aug 2009 B2
7572290 Yodfat et al. Aug 2009 B2
7588597 Frid Sep 2009 B2
7588780 Buiser et al. Sep 2009 B2
7588825 Bell et al. Sep 2009 B2
7608088 Jones et al. Oct 2009 B2
7611530 Pomeranz et al. Nov 2009 B2
7615071 Chobotov Nov 2009 B2
7621928 Thramann et al. Nov 2009 B2
7641680 Palmaz et al. Jan 2010 B2
7645298 Hartley et al. Jan 2010 B2
7651525 Dolan Jan 2010 B2
7666220 Evans et al. Feb 2010 B2
7666333 Lanphere et al. Feb 2010 B2
7691124 Balgobin Apr 2010 B2
7695484 Wallace et al. Apr 2010 B2
7695488 Berenstein et al. Apr 2010 B2
7695507 Rivelli et al. Apr 2010 B2
7695509 Rourke et al. Apr 2010 B2
7704274 Boyle et al. Apr 2010 B2
7708754 Balgobin et al. May 2010 B2
7708755 Davis et al. May 2010 B2
7713264 Murphy et al. May 2010 B2
7736671 DiCarlo et al. Jun 2010 B2
7744610 Hausen Jun 2010 B2
7744652 Morsi Jun 2010 B2
7749242 Tran et al. Jul 2010 B2
7758892 Chen et al. Jul 2010 B1
7763011 Ortiz et al. Jul 2010 B2
7766933 Davis et al. Aug 2010 B2
7766955 Vardi et al. Aug 2010 B2
7769603 Jung et al. Aug 2010 B2
7776079 Gumm Aug 2010 B2
7780645 Jones Aug 2010 B2
7780719 Killion et al. Aug 2010 B2
7799047 Greene et al. Sep 2010 B2
7799052 Balgobin et al. Sep 2010 B2
7803179 Denison Sep 2010 B2
7803180 Burpee et al. Sep 2010 B2
7811300 Feller et al. Oct 2010 B2
7811305 Balgobin et al. Oct 2010 B2
7818084 Boyden et al. Oct 2010 B2
7819891 Balgobin et al. Oct 2010 B2
7819892 Balgobin et al. Oct 2010 B2
7842054 Greene et al. Nov 2010 B2
7842377 Lanphere et al. Nov 2010 B2
7850725 Vardi et al. Dec 2010 B2
7857843 Henderson Dec 2010 B2
7862608 Hogendijk et al. Jan 2011 B2
7875044 Feller et al. Jan 2011 B2
7883526 Jones et al. Feb 2011 B2
7892273 George et al. Feb 2011 B2
7892279 Davidson et al. Feb 2011 B2
7896899 Patterson et al. Mar 2011 B2
7901445 Wallace et al. Mar 2011 B2
7905913 Chew et al. Mar 2011 B2
7914574 Schmid et al. Mar 2011 B2
7914639 Layne et al. Mar 2011 B2
7918881 Andreas et al. Apr 2011 B2
7922755 Acosta et al. Apr 2011 B2
7935142 Gregorich May 2011 B2
7938845 Aganon et al. May 2011 B2
7942925 Yodfat et al. May 2011 B2
7947071 Schmid et al. May 2011 B2
7955382 Flanagan et al. Jun 2011 B2
7959662 Erbel et al. Jun 2011 B2
7963987 Melsheimer et al. Jun 2011 B2
7976527 Cragg et al. Jul 2011 B2
7976823 Lanphere et al. Jul 2011 B2
7985238 Balgobin et al. Jul 2011 B2
7988721 Morris et al. Aug 2011 B2
7993364 Morsi Aug 2011 B2
8002789 Ramzipoor et al. Aug 2011 B2
8003180 Goffena et al. Aug 2011 B2
8007529 Yan Aug 2011 B2
8012192 Eidenschink et al. Sep 2011 B2
8012197 Bashiri et al. Sep 2011 B2
8016853 Griffen et al. Sep 2011 B2
8016870 Chew et al. Sep 2011 B2
8016871 Chew et al. Sep 2011 B2
8016876 Gregorich et al. Sep 2011 B2
8016878 Meyer et al. Sep 2011 B2
8019413 Ferren et al. Sep 2011 B2
8021416 Abrams Sep 2011 B2
8024036 Ferren et al. Sep 2011 B2
8034073 Davis et al. Oct 2011 B2
8038706 Eidenschink et al. Oct 2011 B2
8038708 Case et al. Oct 2011 B2
8048140 Purdy Nov 2011 B2
8052736 Doig et al. Nov 2011 B2
8057495 Pal et al. Nov 2011 B2
8062379 Morsi Nov 2011 B2
8066036 Monetti et al. Nov 2011 B2
8067071 Farnsworth et al. Nov 2011 B2
8070792 Gregorich et al. Dec 2011 B2
8075585 Lee et al. Dec 2011 B2
8095382 Boyden et al. Jan 2012 B2
8100960 Bruszewski Jan 2012 B2
8133256 Wilson et al. Mar 2012 B2
8142456 Rosqueta et al. Mar 2012 B2
8147534 Berez et al. Apr 2012 B2
8147537 Boyden et al. Apr 2012 B2
8163003 Boyden et al. Apr 2012 B2
8172862 Wallace et al. May 2012 B2
8172895 Anderson et al. May 2012 B2
8187315 Clauson et al. May 2012 B1
8202292 Kellett Jun 2012 B2
8211141 Davis et al. Jul 2012 B2
8211160 Garrison et al. Jul 2012 B2
8221447 Solar et al. Jul 2012 B2
8226660 Teoh et al. Jul 2012 B2
8226706 Hartley et al. Jul 2012 B2
8236042 Berez et al. Aug 2012 B2
8246672 Osborne Aug 2012 B2
8252040 Cox Aug 2012 B2
8257421 Berez et al. Sep 2012 B2
8257431 Henderson et al. Sep 2012 B2
8257684 Covalin et al. Sep 2012 B2
8262607 Porter Sep 2012 B2
8262686 Fogarty et al. Sep 2012 B2
8267923 Murphy et al. Sep 2012 B2
8267955 Patterson et al. Sep 2012 B2
8267985 Garcia et al. Sep 2012 B2
8267986 Berez et al. Sep 2012 B2
8273100 Martinez Sep 2012 B2
8273101 Garcia et al. Sep 2012 B2
8277500 Schmid et al. Oct 2012 B2
8282679 Denison Oct 2012 B2
8292914 Morsi Oct 2012 B2
8292944 Schmid et al. Oct 2012 B2
8308751 Gerberding Nov 2012 B2
8313504 Do et al. Nov 2012 B2
8323306 Schaefer et al. Dec 2012 B2
8328860 Strauss et al. Dec 2012 B2
8353943 Kuppurathanam et al. Jan 2013 B2
8357178 Grandfield et al. Jan 2013 B2
8357179 Grandfield et al. Jan 2013 B2
8357180 Feller et al. Jan 2013 B2
8361104 Jones et al. Jan 2013 B2
8361106 Solar et al. Jan 2013 B2
8372062 Murphy et al. Feb 2013 B2
8372114 Hines Feb 2013 B2
8377091 Cruise et al. Feb 2013 B2
8377112 Griffin et al. Feb 2013 B2
8377241 Farnsworth et al. Feb 2013 B2
8382825 Garcia et al. Feb 2013 B2
8388650 Gerberding et al. Mar 2013 B2
8388677 Herrmann Mar 2013 B2
8394136 Hartley et al. Mar 2013 B2
8398670 Amplatz et al. Mar 2013 B2
8398701 Berez et al. Mar 2013 B2
8409267 Berez et al. Apr 2013 B2
8409269 Berez et al. Apr 2013 B2
8414637 Chouinard Apr 2013 B2
8419787 Yodfat et al. Apr 2013 B2
8425541 Masters et al. Apr 2013 B2
8425542 Moftakhar et al. Apr 2013 B2
8425548 Connor Apr 2013 B2
8430922 Jung et al. Apr 2013 B2
8439942 Moran et al. May 2013 B2
8444667 Porter May 2013 B2
8444668 Jones et al. May 2013 B2
8444686 Holman et al. May 2013 B2
8449532 Murphy et al. May 2013 B2
8449592 Wilson et al. May 2013 B2
8454649 Cragg et al. Jun 2013 B2
8460240 Towler Jun 2013 B2
8470013 Duggal et al. Jun 2013 B2
8470035 Cruise et al. Jun 2013 B2
8473030 Greenan et al. Jun 2013 B2
8475517 Jung et al. Jul 2013 B2
8478437 Boyden et al. Jul 2013 B2
8480727 Clarke Jul 2013 B2
8486101 Tran et al. Jul 2013 B2
8491459 Yun Jul 2013 B2
8491646 Schreck Jul 2013 B2
8500788 Berez et al. Aug 2013 B2
8506618 Chouinard et al. Aug 2013 B2
8506619 Ortiz et al. Aug 2013 B2
8512219 Ferren et al. Aug 2013 B2
8512395 Meyer et al. Aug 2013 B2
8523934 Purdy Sep 2013 B2
8529556 Murphy et al. Sep 2013 B2
8529596 Grandfield et al. Sep 2013 B2
8529614 Berez et al. Sep 2013 B2
8529616 Boyle et al. Sep 2013 B2
8529619 Abrams Sep 2013 B2
8535367 Kim et al. Sep 2013 B2
8535590 Milner et al. Sep 2013 B2
8550344 Jung et al. Oct 2013 B2
8551155 Jung et al. Oct 2013 B2
8556953 Berez et al. Oct 2013 B2
8562636 Fogarty et al. Oct 2013 B2
8562667 Cox Oct 2013 B2
8577693 Jung et al. Nov 2013 B2
8597320 Sepetka et al. Dec 2013 B2
8597321 Monstadt et al. Dec 2013 B2
8597323 Plaza et al. Dec 2013 B1
8597342 McKinsey et al. Dec 2013 B2
8597745 Farnsworth et al. Dec 2013 B2
8617132 Golzarian et al. Dec 2013 B2
8623071 Lundkvist et al. Jan 2014 B2
8636760 Garcia et al. Jan 2014 B2
8647377 Kim et al. Feb 2014 B2
8657865 Gumm Feb 2014 B2
8663309 Chobotov Mar 2014 B2
8668716 Hines Mar 2014 B2
8668717 Hines Mar 2014 B2
8671815 Hancock et al. Mar 2014 B2
8696701 Becking et al. Apr 2014 B2
8709062 Dusbabek et al. Apr 2014 B2
8709065 Chobotov Apr 2014 B2
8715312 Burke et al. May 2014 B2
8715317 Janardhan et al. May 2014 B1
8715336 Chu et al. May 2014 B2
8721706 Jung et al. May 2014 B2
8728094 Roorda et al. May 2014 B2
8728145 Chuter et al. May 2014 B2
8728146 Gregorich et al. May 2014 B2
8734502 Orr May 2014 B2
8740966 Brocker et al. Jun 2014 B2
8747430 Porter Jun 2014 B2
8747432 Janardhan et al. Jun 2014 B1
8747455 Greenberg Jun 2014 B2
8747597 Rosqueta et al. Jun 2014 B2
8753371 Janardhan et al. Jun 2014 B1
8764788 Martinez Jul 2014 B2
8769796 Bourang et al. Jul 2014 B2
8771294 Sepetka et al. Jul 2014 B2
8771341 Strauss et al. Jul 2014 B2
8771342 Vardi Jul 2014 B2
8784446 Janardhan et al. Jul 2014 B1
8784475 Martinson et al. Jul 2014 B2
8784477 Bregulla et al. Jul 2014 B2
8795345 Grandfield et al. Aug 2014 B2
8795346 Alkhatib Aug 2014 B2
8795347 Bourang et al. Aug 2014 B2
8801772 Shobayashi et al. Aug 2014 B2
8808347 Bourang et al. Aug 2014 B2
8808361 Strauss et al. Aug 2014 B2
8813625 Janardhan et al. Aug 2014 B1
8821564 Schreck et al. Sep 2014 B2
8828071 Bourang et al. Sep 2014 B2
8840867 Sophie et al. Sep 2014 B2
8845679 Janardhan et al. Sep 2014 B1
20010000797 Mazzocchi May 2001 A1
20010001835 Greene et al. May 2001 A1
20010009996 Ferrera et al. Jul 2001 A1
20010016766 Vardi et al. Aug 2001 A1
20010037137 Vardi et al. Nov 2001 A1
20010056281 Wallace et al. Dec 2001 A1
20020002382 Wallace et al. Jan 2002 A1
20020018752 Krall et al. Feb 2002 A1
20020042628 Chin et al. Apr 2002 A1
20020058962 Wallace et al. May 2002 A1
20020082620 Lee Jun 2002 A1
20020082636 Sawhney et al. Jun 2002 A1
20020087077 Wallace et al. Jul 2002 A1
20020107534 Schaefer et al. Aug 2002 A1
20020116047 Vardi et al. Aug 2002 A1
20020120276 Greene et al. Aug 2002 A1
20020128671 Wallace et al. Sep 2002 A1
20020133190 Horton et al. Sep 2002 A1
20020143348 Wallace et al. Oct 2002 A1
20020151926 Wallace et al. Oct 2002 A1
20020151965 Roth Oct 2002 A1
20020156516 Vardi et al. Oct 2002 A1
20020169473 Sepetka et al. Nov 2002 A1
20020177855 Greene et al. Nov 2002 A1
20030014007 Eidenschink et al. Jan 2003 A1
20030014075 Rosenbluth et al. Jan 2003 A1
20030018294 Cox Jan 2003 A1
20030018356 Schaefer et al. Jan 2003 A1
20030065375 Eskuri Apr 2003 A1
20030074049 Hoganson et al. Apr 2003 A1
20030074056 Killion et al. Apr 2003 A1
20030083676 Wallace May 2003 A1
20030083737 Greene et al. May 2003 A1
20030088311 Greene et al. May 2003 A1
20030093097 Avellanet et al. May 2003 A1
20030093108 Avellanet et al. May 2003 A1
20030093111 Ken et al. May 2003 A1
20030100945 Yodfat et al. May 2003 A1
20030109917 Rudin et al. Jun 2003 A1
20030130689 Wallace et al. Jul 2003 A1
20030135264 Whalen et al. Jul 2003 A1
20030139802 Wulfman Jul 2003 A1
20030159920 Roth Aug 2003 A1
20030181927 Wallace Sep 2003 A1
20030187473 Berenstein et al. Oct 2003 A1
20030195553 Wallace et al. Oct 2003 A1
20030195606 Davidson et al. Oct 2003 A1
20030223955 Whalen et al. Dec 2003 A1
20040002752 Griffin et al. Jan 2004 A1
20040015227 Vardi et al. Jan 2004 A1
20040045554 Schaefer et al. Mar 2004 A1
20040059370 Greene et al. Mar 2004 A1
20040091543 Bell et al. May 2004 A1
20040093014 Ho et al. May 2004 A1
20040098027 Teoh et al. May 2004 A1
20040098028 Martinez May 2004 A1
20040111112 Hoffmann Jun 2004 A1
20040111142 Rourke et al. Jun 2004 A1
20040115164 Pierce et al. Jun 2004 A1
20040158282 Jones et al. Aug 2004 A1
20040161451 Pierce et al. Aug 2004 A1
20040181253 Sepetka et al. Sep 2004 A1
20040186551 Kao et al. Sep 2004 A1
20040193246 Ferrera Sep 2004 A1
20040210249 Fogarty et al. Oct 2004 A1
20040215331 Chew et al. Oct 2004 A1
20040220663 Rivelli, Jr. Nov 2004 A1
20040243168 Ferrera et al. Dec 2004 A1
20040243216 Gregorich Dec 2004 A1
20040249435 Andreas et al. Dec 2004 A1
20040249439 Richter et al. Dec 2004 A1
20040260384 Allen Dec 2004 A1
20050004660 Rosenbluth et al. Jan 2005 A1
20050010281 Yodfat et al. Jan 2005 A1
20050015110 Fogarty et al. Jan 2005 A1
20050021077 Chin et al. Jan 2005 A1
20050033349 Jones et al. Feb 2005 A1
20050033350 Ken et al. Feb 2005 A1
20050065592 Holzer Mar 2005 A1
20050075405 Wilson et al. Apr 2005 A1
20050080445 Sawhney et al. Apr 2005 A1
20050090888 Hines et al. Apr 2005 A1
20050095428 Dicarlo et al. May 2005 A1
20050096728 Ramer May 2005 A1
20050107863 Brown May 2005 A1
20050119687 Dacey et al. Jun 2005 A1
20050131516 Greenhalgh Jun 2005 A1
20050131518 Hartley et al. Jun 2005 A1
20050133046 Becker et al. Jun 2005 A1
20050149159 Andreas et al. Jul 2005 A1
20050149164 Rivelli Jul 2005 A1
20050171572 Martinez Aug 2005 A1
20050171597 Boatman et al. Aug 2005 A1
20050192618 Porter Sep 2005 A1
20050192621 Wallace et al. Sep 2005 A1
20050192661 Griffen et al. Sep 2005 A1
20050209674 Kutscher et al. Sep 2005 A1
20050228434 Amplatz et al. Oct 2005 A1
20050251247 Roth Nov 2005 A1
20050267510 Razack Dec 2005 A1
20050267568 Berez et al. Dec 2005 A1
20050277978 Greenhalgh Dec 2005 A1
20050283220 Gobran et al. Dec 2005 A1
20060036045 Wilson et al. Feb 2006 A1
20060036281 Patterson et al. Feb 2006 A1
20060052816 Bates et al. Mar 2006 A1
20060058834 Do et al. Mar 2006 A1
20060079923 Chhabra et al. Apr 2006 A1
20060085061 Vardi et al. Apr 2006 A1
20060116709 Sepetka et al. Jun 2006 A1
20060116712 Sepetka et al. Jun 2006 A1
20060116713 Sepetka et al. Jun 2006 A1
20060136033 Hermann et al. Jun 2006 A1
20060149299 Greene et al. Jul 2006 A1
20060155323 Porter et al. Jul 2006 A1
20060155367 Hines Jul 2006 A1
20060184195 Schaefer et al. Aug 2006 A1
20060184196 Schaefer et al. Aug 2006 A1
20060206196 Porter Sep 2006 A1
20060206200 Garcia et al. Sep 2006 A1
20060206201 Garcia et al. Sep 2006 A1
20060224230 Rivelli et al. Oct 2006 A1
20060229714 Lombardi et al. Oct 2006 A1
20060235464 Avellanet et al. Oct 2006 A1
20060241690 Amplatz et al. Oct 2006 A1
20060241740 Vardi et al. Oct 2006 A1
20060251695 Henson et al. Nov 2006 A1
20060251700 Henson et al. Nov 2006 A1
20060271149 Berez et al. Nov 2006 A1
20060271153 Garcia et al. Nov 2006 A1
20060276831 Porter et al. Dec 2006 A1
20060292206 Kim et al. Dec 2006 A1
20070016233 Ferrera et al. Jan 2007 A1
20070021816 Rudin Jan 2007 A1
20070031584 Roth Feb 2007 A1
20070032855 Davidson et al. Feb 2007 A1
20070050008 Kim et al. Mar 2007 A1
20070055355 Kim et al. Mar 2007 A1
20070060994 Gobran et al. Mar 2007 A1
20070061005 Kim et al. Mar 2007 A1
20070067015 Jones et al. Mar 2007 A1
20070083257 Pal et al. Apr 2007 A1
20070088368 Acosta et al. Apr 2007 A1
20070088387 Eskridge et al. Apr 2007 A1
20070100301 Gumm May 2007 A1
20070106311 Wallace et al. May 2007 A1
20070129786 Beach et al. Jun 2007 A1
20070135907 Wilson et al. Jun 2007 A1
20070150041 Evans et al. Jun 2007 A1
20070150045 Ferrera Jun 2007 A1
20070167747 Borgert et al. Jul 2007 A1
20070175536 Monetti et al. Aug 2007 A1
20070176333 Greene et al. Aug 2007 A1
20070207186 Scanlon et al. Sep 2007 A1
20070219578 Solar et al. Sep 2007 A1
20070219610 Israel Sep 2007 A1
20070219619 Dieck et al. Sep 2007 A1
20070225794 Thramann et al. Sep 2007 A1
20070239261 Bose et al. Oct 2007 A1
20070265656 Amplatz et al. Nov 2007 A1
20070299464 Cruise et al. Dec 2007 A1
20070299498 Perez et al. Dec 2007 A1
20080004653 Sherman et al. Jan 2008 A1
20080004692 Henson et al. Jan 2008 A1
20080031919 Henson et al. Feb 2008 A1
20080033341 Grad Feb 2008 A1
20080033366 Matson et al. Feb 2008 A1
20080039933 Yodfat et al. Feb 2008 A1
20080097495 Feller et al. Apr 2008 A1
20080103585 Monstadt et al. May 2008 A1
20080114391 Dieck et al. May 2008 A1
20080114436 Dieck et al. May 2008 A1
20080125852 Garrison et al. May 2008 A1
20080147100 Wallace Jun 2008 A1
20080152686 Henson et al. Jun 2008 A1
20080161936 Feller et al. Jul 2008 A1
20080195137 Alleyne et al. Aug 2008 A1
20080200945 Amplatz et al. Aug 2008 A1
20080221600 Dieck et al. Sep 2008 A1
20080249608 Dave Oct 2008 A1
20080281350 Sepetka et al. Nov 2008 A1
20080312732 Hartley et al. Dec 2008 A1
20080319521 Norris et al. Dec 2008 A1
20080319525 Tieu et al. Dec 2008 A1
20080319533 Lehe Dec 2008 A1
20090062834 Moftakhar et al. Mar 2009 A1
20090062841 Amplatz et al. Mar 2009 A1
20090069880 Vonderwalde et al. Mar 2009 A1
20090082846 Chobotov Mar 2009 A1
20090088832 Chew et al. Apr 2009 A1
20090105748 Fogarty et al. Apr 2009 A1
20090112249 Miles et al. Apr 2009 A1
20090112250 Greene et al. Apr 2009 A1
20090118761 Masters et al. May 2009 A1
20090125053 Ferrera et al. May 2009 A1
20090132028 Vardi et al. May 2009 A1
20090149864 Porter Jun 2009 A1
20090164013 Cruise et al. Jun 2009 A1
20090171437 Brocker et al. Jul 2009 A1
20090177268 Lundkvist et al. Jul 2009 A1
20090192536 Berez et al. Jul 2009 A1
20090198318 Berez et al. Aug 2009 A1
20090227976 Calabria et al. Sep 2009 A1
20090228029 Lee Sep 2009 A1
20090232869 Greene et al. Sep 2009 A1
20090248135 Bruszewski et al. Oct 2009 A1
20090254111 Monstadt et al. Oct 2009 A1
20090270970 Yodfat et al. Oct 2009 A1
20090270974 Berez et al. Oct 2009 A1
20090275974 Marchand et al. Nov 2009 A1
20090287241 Berez et al. Nov 2009 A1
20090287288 Berez et al. Nov 2009 A1
20090287291 Becking et al. Nov 2009 A1
20090287292 Becking et al. Nov 2009 A1
20090287294 Rosqueta et al. Nov 2009 A1
20090292348 Berez et al. Nov 2009 A1
20090297582 Meyer et al. Dec 2009 A1
20090299326 Morsi Dec 2009 A1
20090299390 Dehnad Dec 2009 A1
20090299448 Timko et al. Dec 2009 A1
20090318941 Sepetka et al. Dec 2009 A1
20090318947 Garcia et al. Dec 2009 A1
20090318948 Linder et al. Dec 2009 A1
20090318949 Ganpath et al. Dec 2009 A1
20090319017 Berez et al. Dec 2009 A1
20090319023 Hildebrand et al. Dec 2009 A1
20100004671 Gerberding et al. Jan 2010 A1
20100004726 Hancock et al. Jan 2010 A1
20100010624 Berez et al. Jan 2010 A1
20100016833 Ogle et al. Jan 2010 A1
20100023105 Levy et al. Jan 2010 A1
20100036412 Porter et al. Feb 2010 A1
20100042200 Richter et al. Feb 2010 A1
20100063472 Becker et al. Mar 2010 A1
20100063531 Rudakov et al. Mar 2010 A1
20100069948 Veznedaroglu et al. Mar 2010 A1
20100082091 Berez et al. Apr 2010 A1
20100094335 Gerberding et al. Apr 2010 A1
20100106240 Duggal et al. Apr 2010 A1
20100114302 Tzafriri et al. May 2010 A1
20100131002 Connor et al. May 2010 A1
20100152828 Pakbaz et al. Jun 2010 A1
20100152834 Hannes et al. Jun 2010 A1
20100152837 Lundkvist et al. Jun 2010 A1
20100168781 Berenstein et al. Jul 2010 A1
20100174301 Wallace et al. Jul 2010 A1
20100179640 Reith Jul 2010 A1
20100179645 Chen et al. Jul 2010 A1
20100198250 Ricci et al. Aug 2010 A1
20100198334 Yodfat et al. Aug 2010 A1
20100222804 Murphy et al. Sep 2010 A1
20100222864 Rivelli et al. Sep 2010 A1
20100274276 Chow et al. Oct 2010 A1
20100274346 Chouinard et al. Oct 2010 A1
20100280452 Chen et al. Nov 2010 A1
20100305681 Gumm Dec 2010 A1
20100312326 Chuter et al. Dec 2010 A1
20100318173 Kolandaivelu et al. Dec 2010 A1
20100324660 Denison Dec 2010 A1
20110004294 Bialas Jan 2011 A1
20110005062 Greene et al. Jan 2011 A1
20110009940 Grandfield et al. Jan 2011 A1
20110009941 Grandfield et al. Jan 2011 A1
20110009950 Grandfield et al. Jan 2011 A1
20110022149 Cox et al. Jan 2011 A1
20110039967 Wilson et al. Feb 2011 A1
20110046658 Connor et al. Feb 2011 A1
20110046716 Parkinson et al. Feb 2011 A1
20110054511 Henson et al. Mar 2011 A1
20110054589 Bashiri et al. Mar 2011 A1
20110066221 White et al. Mar 2011 A1
20110082427 Golzarian et al. Apr 2011 A1
20110082491 Sepetka et al. Apr 2011 A1
20110082533 Vardi et al. Apr 2011 A1
20110089592 Farnsworth et al. Apr 2011 A1
20110092997 Kang Apr 2011 A1
20110098814 Monstadt et al. Apr 2011 A1
20110118777 Patterson et al. May 2011 A1
20110137332 Sepetka et al. Jun 2011 A1
20110137405 Wilson et al. Jun 2011 A1
20110144669 Becking et al. Jun 2011 A1
20110144686 Wilson et al. Jun 2011 A1
20110144740 Molaei et al. Jun 2011 A1
20110152993 Marchand et al. Jun 2011 A1
20110152996 Acosta et al. Jun 2011 A1
20110152998 Berez et al. Jun 2011 A1
20110166588 Connor et al. Jul 2011 A1
20110166592 Garcia et al. Jul 2011 A1
20110166641 Bales et al. Jul 2011 A1
20110182998 Reb et al. Jul 2011 A1
20110184451 Sahl Jul 2011 A1
20110184452 Huynh et al. Jul 2011 A1
20110184453 Levy et al. Jul 2011 A1
20110184454 Barry et al. Jul 2011 A1
20110184455 Keeley et al. Jul 2011 A1
20110184456 Grandfield et al. Jul 2011 A1
20110196413 Wallace et al. Aug 2011 A1
20110202085 Loganathan et al. Aug 2011 A1
20110208227 Becking Aug 2011 A1
20110213406 Aganon et al. Sep 2011 A1
20110224776 Sepetka et al. Sep 2011 A1
20110230957 Bonsignore et al. Sep 2011 A1
20110238105 Gelbart et al. Sep 2011 A1
20110245862 Dieck et al. Oct 2011 A1
20110245863 Martinez Oct 2011 A1
20110264192 Hartley et al. Oct 2011 A1
20110265943 Rosqueta et al. Nov 2011 A1
20110276071 Connor et al. Nov 2011 A1
20110282378 Murphy et al. Nov 2011 A1
20110286925 Lerouge et al. Nov 2011 A1
20110288627 Hartley et al. Nov 2011 A1
20110307044 Bourang et al. Dec 2011 A1
20110307045 Bourang et al. Dec 2011 A1
20110307046 Bourang et al. Dec 2011 A1
20110307052 Bourang et al. Dec 2011 A1
20110313443 Lorenzo et al. Dec 2011 A1
20110313512 Hartley et al. Dec 2011 A1
20110319926 Becking et al. Dec 2011 A1
20110319928 Griffin et al. Dec 2011 A1
20120004682 Connor Jan 2012 A1
20120004719 Gregorich et al. Jan 2012 A1
20120016462 Gregorich et al. Jan 2012 A1
20120041540 Shobayashi et al. Feb 2012 A1
20120046676 Morsi Feb 2012 A1
20120053670 Purdy Mar 2012 A1
20120055614 Hancock et al. Mar 2012 A1
20120071911 Sadasivan et al. Mar 2012 A1
20120078285 Griffin Mar 2012 A1
20120089174 Chen et al. Apr 2012 A1
20120116352 Rangi May 2012 A1
20120116441 Yamanaka et al. May 2012 A1
20120116442 Monstadt et al. May 2012 A1
20120130479 Chuter et al. May 2012 A1
20120143237 Cam et al. Jun 2012 A1
20120143317 Cam et al. Jun 2012 A1
20120165919 Cox et al. Jun 2012 A1
20120165920 Meyer et al. Jun 2012 A1
20120172921 Yamanaka et al. Jul 2012 A1
20120172972 Meyer et al. Jul 2012 A1
20120172977 Bregulla et al. Jul 2012 A1
20120179192 Fogarty et al. Jul 2012 A1
20120197283 Marchand et al. Aug 2012 A1
20120209309 Chen et al. Aug 2012 A1
20120209311 Grandfield et al. Aug 2012 A1
20120215250 Grandfield et al. Aug 2012 A1
20120221095 Berez et al. Aug 2012 A1
20120238644 Gong et al. Sep 2012 A1
20120239074 Aboytes et al. Sep 2012 A1
20120245674 Molaei et al. Sep 2012 A1
20120245675 Molaei et al. Sep 2012 A1
20120253369 Morsi Oct 2012 A1
20120253377 Slazas et al. Oct 2012 A1
20120253448 Hartley et al. Oct 2012 A1
20120259354 Kellett Oct 2012 A1
20120259404 Tieu et al. Oct 2012 A1
20120265287 Sharma et al. Oct 2012 A1
20120271200 Martinson et al. Oct 2012 A1
20120271399 Perkins et al. Oct 2012 A1
20120277784 Berez et al. Nov 2012 A1
20120283764 Solar et al. Nov 2012 A1
20120283765 Berez et al. Nov 2012 A1
20120283768 Cox et al. Nov 2012 A1
20120283769 Cruise et al. Nov 2012 A1
20120283815 Berez et al. Nov 2012 A1
20120289995 Constant et al. Nov 2012 A1
20120296361 Cam et al. Nov 2012 A1
20120296362 Cam et al. Nov 2012 A1
20120303052 Connor Nov 2012 A1
20120303108 Fogarty et al. Nov 2012 A1
20120303112 Armstrong et al. Nov 2012 A1
20120310270 Murphy et al. Dec 2012 A1
20120310271 Kwon Dec 2012 A1
20120310611 Sadasivan et al. Dec 2012 A1
20120316598 Becking et al. Dec 2012 A1
20120316632 Gao Dec 2012 A1
20120316638 Grad et al. Dec 2012 A1
20120323268 Martinez Dec 2012 A1
20120323309 Cattaneo Dec 2012 A1
20120323547 Baloch et al. Dec 2012 A1
20120330341 Becking et al. Dec 2012 A1
20120330343 Kim et al. Dec 2012 A1
20120330347 Becking et al. Dec 2012 A1
20120330402 Vad et al. Dec 2012 A1
20130012979 Amplatz et al. Jan 2013 A1
20130018220 Vad et al. Jan 2013 A1
20130018409 Le et al. Jan 2013 A1
20130023903 Roorda et al. Jan 2013 A1
20130035712 Theobald et al. Feb 2013 A1
20130041454 Dobson et al. Feb 2013 A1
20130045182 Gong et al. Feb 2013 A1
20130046371 Greenberg et al. Feb 2013 A1
20130053872 Hansen Feb 2013 A1
20130053944 Welch Feb 2013 A1
20130060317 Dusbabek et al. Mar 2013 A1
20130060322 Leynov et al. Mar 2013 A1
20130066357 Aboytes et al. Mar 2013 A1
20130066359 Murphy et al. Mar 2013 A1
20130066360 Becking et al. Mar 2013 A1
20130066413 Jin et al. Mar 2013 A1
20130066415 Hocking Mar 2013 A1
20130072959 Wu et al. Mar 2013 A1
20130085518 Trommeter et al. Apr 2013 A1
20130085522 Becking et al. Apr 2013 A1
20130089576 Maitland et al. Apr 2013 A1
20130090682 Bachman et al. Apr 2013 A1
20130090719 Bales et al. Apr 2013 A1
20130090721 Bales et al. Apr 2013 A1
20130095087 Shalaby et al. Apr 2013 A1
20130103074 Riina et al. Apr 2013 A1
20130103135 Vinluan Apr 2013 A1
20130108574 Chevalier et al. May 2013 A1
20130116659 Porter May 2013 A1
20130116722 Aboytes et al. May 2013 A1
20130116774 Strauss et al. May 2013 A1
20130123830 Becking et al. May 2013 A1
20130123899 Leopold et al. May 2013 A1
20130123901 Connor et al. May 2013 A1
20130131711 Bowman May 2013 A1
20130131716 Cruise et al. May 2013 A1
20130131780 Armstrong et al. May 2013 A1
20130131786 Chobotov May 2013 A1
20130146173 Krivoruchko et al. Jun 2013 A1
20130150946 Hartley et al. Jun 2013 A1
20130166010 Vad Jun 2013 A1
20130166017 Cartledge et al. Jun 2013 A1
20130172925 Garcia et al. Jul 2013 A1
20130172975 Berez et al. Jul 2013 A1
20130172976 Garcia et al. Jul 2013 A1
20130190795 Matson et al. Jul 2013 A1
20130190800 Murphy et al. Jul 2013 A1
20130190805 Slazas et al. Jul 2013 A1
20130197547 Fukuoka et al. Aug 2013 A1
20130197570 Ebata et al. Aug 2013 A1
20130197617 Armstrong et al. Aug 2013 A1
20130197624 Armstrong et al. Aug 2013 A1
20130204288 Johnson et al. Aug 2013 A1
20130204289 Dasnurkar et al. Aug 2013 A1
20130204290 Clarke et al. Aug 2013 A1
20130204347 Armstrong et al. Aug 2013 A1
20130204351 Cox et al. Aug 2013 A1
20130204354 Adams Aug 2013 A1
20130211443 Cragg et al. Aug 2013 A1
20130211492 Schneider et al. Aug 2013 A1
20130211497 Charlebois et al. Aug 2013 A1
20130211498 Buckley et al. Aug 2013 A1
20130211505 Robison Aug 2013 A1
20130211507 LaDuca et al. Aug 2013 A1
20130218191 Heltai Aug 2013 A1
20130226276 Newell et al. Aug 2013 A1
20130226278 Newell et al. Aug 2013 A1
20130231695 Malek Sep 2013 A1
20130231732 Vonderwalde et al. Sep 2013 A1
20130238083 Duggal et al. Sep 2013 A1
20130245606 Stam et al. Sep 2013 A1
20130245667 Marchand et al. Sep 2013 A1
20130245745 Vong et al. Sep 2013 A1
20130252900 Reb et al. Sep 2013 A1
20130253086 Wilson et al. Sep 2013 A1
20130253572 Molaei et al. Sep 2013 A1
20130253631 Schmid et al. Sep 2013 A1
20130253634 Wilson et al. Sep 2013 A1
20130261728 Perkins et al. Oct 2013 A1
20130261730 Bose et al. Oct 2013 A1
20130261732 Perkins et al. Oct 2013 A1
20130267986 Hines Oct 2013 A1
20130268046 Gerberding et al. Oct 2013 A1
20130268053 Molaei et al. Oct 2013 A1
20130274862 Cox et al. Oct 2013 A1
20130274863 Cox et al. Oct 2013 A1
20130274866 Cox et al. Oct 2013 A1
20130274868 Cox et al. Oct 2013 A1
20130282096 Berez et al. Oct 2013 A1
20130289690 Thapliyal Oct 2013 A1
20130289713 Pearson et al. Oct 2013 A1
20130289714 Strauss et al. Oct 2013 A1
20130302251 Constant et al. Nov 2013 A1
20130304109 Abrams et al. Nov 2013 A1
20130310687 Takizawa et al. Nov 2013 A1
20130325053 Porter et al. Dec 2013 A1
20130331883 Strauss et al. Dec 2013 A1
20130338688 Rehman et al. Dec 2013 A1
20130344159 Moine et al. Dec 2013 A1
20130345738 Eskridge Dec 2013 A1
20130345785 Hartley et al. Dec 2013 A1
20140005698 Eskridge Jan 2014 A1
20140012303 Heipl Jan 2014 A1
20140012307 Franano et al. Jan 2014 A1
20140012363 Franano et al. Jan 2014 A1
20140018843 Berez et al. Jan 2014 A1
20140018902 Myr Jan 2014 A1
20140025151 Gao Jan 2014 A1
20140025154 Liang et al. Jan 2014 A1
20140031858 Bhagchandani et al. Jan 2014 A1
20140031918 Newell et al. Jan 2014 A1
20140031920 Malek Jan 2014 A1
20140039536 Cully et al. Feb 2014 A1
20140039606 Rudakov et al. Feb 2014 A1
20140046338 Grandfield et al. Feb 2014 A1
20140047694 Monstadt et al. Feb 2014 A1
20140052168 Sawhney Feb 2014 A1
20140052233 Cox et al. Feb 2014 A1
20140058420 Hannes et al. Feb 2014 A1
20140058436 Rosenbluth et al. Feb 2014 A1
20140058498 Hannes et al. Feb 2014 A1
20140058500 Lundkvist et al. Feb 2014 A1
20140074149 Garcia et al. Mar 2014 A1
20140081313 Elliott Mar 2014 A1
20140081374 Kim et al. Mar 2014 A1
20140082924 Lundkvist et al. Mar 2014 A1
20140083969 Porter Mar 2014 A1
20140088690 Fogarty et al. Mar 2014 A1
20140094896 Berez et al. Apr 2014 A1
20140099374 Golzarian et al. Apr 2014 A1
20140100647 Bourang Apr 2014 A1
20140114342 Berez et al. Apr 2014 A1
20140114343 Lee et al. Apr 2014 A1
20140121744 Kusleika May 2014 A1
20140121745 Kusleika et al. May 2014 A1
20140121746 Kusleika et al. May 2014 A1
20140121752 Losordo et al. May 2014 A1
20140128901 Kang et al. May 2014 A1
20140128907 Hui et al. May 2014 A1
20140128957 Losordo et al. May 2014 A1
20140130965 Banks et al. May 2014 A1
20140135810 Divino et al. May 2014 A1
20140135811 Divino et al. May 2014 A1
20140135812 Divino et al. May 2014 A1
20140142611 Plaza et al. May 2014 A1
20140163604 Monstadt Jun 2014 A1
20140172001 Becking et al. Jun 2014 A1
20140172067 Brown et al. Jun 2014 A1
20140172071 Berez et al. Jun 2014 A1
20140180377 Bose et al. Jun 2014 A1
20140180387 Khenansho et al. Jun 2014 A1
20140180397 Gerberding et al. Jun 2014 A1
20140188208 Hancock et al. Jul 2014 A1
20140194973 Chobotov Jul 2014 A1
20140200607 Sepetka et al. Jul 2014 A1
20140200648 Newell et al. Jul 2014 A1
20140207162 Tran et al. Jul 2014 A1
20140207180 Ferrera Jul 2014 A1
20140214071 Thomas Jul 2014 A1
20140222128 Dusbabek et al. Aug 2014 A1
20140222130 Kusleika Aug 2014 A1
20140236216 Gerberding Aug 2014 A1
20140243951 Orr Aug 2014 A1
20140249614 Levi et al. Sep 2014 A1
20140249616 Strauss et al. Sep 2014 A1
20140249620 Carman et al. Sep 2014 A1
20140260928 Janardhan et al. Sep 2014 A1
20140265096 Janardhan et al. Sep 2014 A1
20140277100 Kang Sep 2014 A1
20140277361 Farhat et al. Sep 2014 A1
20140277370 Brocker et al. Sep 2014 A1
20140277391 Layman et al. Sep 2014 A1
20140288633 Burke et al. Sep 2014 A1
20140296358 Maitland et al. Oct 2014 A1
Foreign Referenced Citations (1)
Number Date Country
PCTUS2009002537 Apr 2009 WO
Non-Patent Literature Citations (2)
Entry
U.S. Appl. No. 12/387,637, filed 2009, Connor et al.
U.S. Appl. No. 13/889,451, filed 2013, Connor et al.
Continuation in Parts (1)
Number Date Country
Parent 12592116 Nov 2009 US
Child 14562725 US